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“If we play without objectives, in the long run our decisions will become exclusively 
reactive and we will be made to play our opponents game, and not ours”.!!
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1. INTRODUCTION!
!
1.1 An overview on Neurosteroids  
 
In 1981, the french physiologist Etienne Baulieu coined the term “neurosteroids”1 to 
describe steroids whose accumulation occurs in the nervous system independently, at 
least in part, of supply by the steroidogenic endocrine glands2, 3. This term, widely 
accepted by scientific community, is today commonly used to identify a class of steroids 
which can be synthesized de novo2, 4 in the CNS (central nervous system), especially 
within glia, from sterol precursors, involved in the modulation of neuronal excitability 
by non-rapid genomic actions. Precursors for their synthesis, which is performed locally 
in the hippocampus and other brain structures5, are progesterone, deoxycorticosterone 
and testosterone, steroid hormones mainly synthesized in the gonads, adrenal gland and 
feto-placental unit. The major pathways in steroids biosynthesis is shown in Figure 1.1.!
Figure 1.1 Schematic representation of the metabolic pathways of cholesterol in steroids 
biosynthesis.!
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These hormones derive from pregnenolone, the first product of cholesterol metabolism, 
found in the brain6 at concentrations about one order of magnitude larger than those of 
its other derivatives, as might be expected from a precursor-to-product relationship7.!
The derivatives neurosteroids are basically A-ring reduced metabolites of these steroids 
and, based on structural features, neurosteroids can be classified as pregnane 
n e u r o s t e r o i d s , s u c h a s a l l o p r e g n a n o l o n e a n d T H D O C 
(allotetrahydrodeoxycorticosterone), androstane neurosteroids, such as androstanediol 
and etiocholanone, and sulfated neurosteroids, such as PS (pregnenolone sulfate), and 
DHEAS (dehydroepiandrosterone sulfate). Studies during the past two decades have 
uncovered that progesterone and deoxycorticosterone serve as precursors for the 
endogenous neurosteroids allopregnanolone, 5α-pregnane-3α-ol-20-one, and THDOC, 
5α-pregnane-3α,21-diol-20-one, respectively. Testosterone-derived androgens such as 
androstanediol, 5α-androstane-3α,17β-diol, and estradiol can either be considered as 
neurosteroids.!
!
The conversion of parent steroids into the corresponding neurosteroids mostly consists 
in sequential reduction, mediated by 5α-reductase and 3α-HSOR (3α-hydroxysteroid 
oxidoreductase). These reductions occur in peripheral tissues, such as reproductive 
endocrine, liver and skin8. Anyway, it’s an evidence that neurosteroids biosynthetic 
enzymes are operating in human brain too9; as a matter of fact, 5α-reductase has been 
identified in both neurons and glial cells10. 5α-reductase and 3α-HSOR have been found 
in human neocortex and subcortical white matter, as well as in hippocampal tissues8, 10, 
thus we can assume that steroid precursor, peripherally synthesized, enter the brain and 
here are available for enzymatic pool to biosynthesize neurosteroids. At the same time, 
in brain region such as cortex, hippocampus and amygdala, are located enzymes 
required to convert cholesterol to pregnenolone, CYP450scc (cytochrome P450 
cholesterol side-chain cleavage enzyme), and to sequently convert pregnenolone to 
progesterone, 3β-hydroxysteroid dehydrogenase, so it is possible for these brain regions 
to synthesize neurosteroids directly in situ.  
On the other hand, glial cells and principal neurons produce neurosteroids de novo9, 11 
from their steroid precursors. In this regard can be mentioned the fact that 
allopregnanolone persists in the brain after adrenalectomy and gonadectomy or after 
pharmacological suppression of adrenal and gonadal secretions12, indicating that 
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allopregnanolone can be synthesized de novo in brain via 5α-reduction of progesterone, 
thus some regulatory mechanisms of neurosteroids biosynthesis in brain still remain 
unclear.!
Since neurosteroids are highly lipophilic, they can easily pass the blood-brain barrier 
and so, from the peripheral tissues where they’ve been synthesized, they can accumulate 
in the brain and modulate their interaction with transmembrane receptors and ion 
channels13. Neurosteroids are endogenous regulators of neuronal excitability, since their 
major target is the GABAA receptor14, a subtype of receptor of the GABA (γ-
aminobutyric acid), mediating the bulk of synaptic inhibition in the CNS.  
Structurally, GABAA receptors are heteropentamers with five protein subunits that form 
the chloride ion channels15 (common structure of the receptor complex is shown in 
Figure 1.2). !
!
!
!
!
!
!
Figure 1.2 GABAA receptor complex visualized by electron microscopy and, on the right, the 
common α1, β2, γ2 GABAA structure.  !
There are seven different classes of subunits, some of which have multiple homologous 
variants (α1-6, β1-3, γ1-3, σ1-3, δ, ε, θ); most GABAA receptors are composed of α, β and 
γ or δ subunits16. GABA activates the opening of chloride ion channels, permitting 
chloride ion influx and, ultimately, hyperpolarization. GABAA receptors action prevents 
potential generation by short-circuiting the depolarization produced by excitatory 
neurotransmission17.  
Depending on their chemical structure, neurosteroids can be positive or negative 
modulators of the GABA-ergic system13, 18; for example, allopregnanolone, THDOC 
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and androstanediol are potent positive allosteric modulators of GABAA receptors19, 20. 
The binding site for neurosteroids is proposed to be distinct from that of the GABA, 
benzodiazepine and barbiturate sites. Although the exact location of neurosteroids 
binding site is currently unknown, it has been shown that a highly conserved glutamine 
at position 241 in the M1 domain of the α-subunit plays a key role in neurosteroids 
modulation21.  
Basically, exposure to neurosteroids enhances the open probability of the GABAA 
receptor chloride channel, so that the mean open time is increased and the mean closed 
time is decreased. This increases the chloride current through the channel, ultimately 
resulting in a reduction of neuronal excitability22, 23.  
Neurosteroids mechanism of interaction shows both acute and chronic effects. 
Regarding the acute effects, it’s and evidence that they are not due to interactions with 
steroid hormone receptors, that usually regulate genes transcription; we can state that 
the genomic effects of neurosteroids are mainly related to their metabolic 
interconversion to traditional steroids24. On the other side, their chronic effects are due 
both to genomic (intracellular steroid receptors) and non-genomic rapid actions (ion 
channels and membrane receptors) in the brain. This is supported by the observation 
that the effects of neurosteroids raise quickly, while steroid hormone actions mediated 
by intracellular receptors take more time to occur and have prolonged duration25, and 
also that neurosteroids don’t exhibit high affinity towards nuclear steroid hormone 
receptors24, 26. Moreover, studies in PR (progesterone receptor), knockout mice have 
conclusively demonstrated that the classical steroid receptor is not required for the 
sedative, anxiolytic, and anticonvulsant activity of progesterone and related 
neurosteroids27, and neurosteroids have been demonstrated to directly modulate the 
activity of ligand-gated ion channels, most notably GABAA receptors, as previously 
mentioned22, 23.  
The physiological and pharmacological profile of major neurosteroids has been widely 
investigated; in general, neurosteroids that are 3α-hydroxy-pregnane derivatives such as 
allopregnanolone, pregnanolone, and THDOC elicit sedative, anxiolytic, and 
anticonvulsant actions while PS and DHEAS are excitatory and produce memory 
enhancing and anxiogenic effects.  
To mention but a few more in details, neurosteroids are broad spectrum anticonvulsant 
agents, as demonstrated for epilepsy28, 29, are released during physiological stress13, 30, 
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have a crucial role in depression31 (e.g. allopregnanolone, that both alleviates depressive 
behavior in animal models of depression and mediates the antidepressant action of 
drugs like fluoxetine32), have been widely recognized to modulate learning and memory 
processes in young, aged and in pharmacological models of amnesia.  
Another aspect strongly highlighted by evidences, though the precise mechanism 
underlying is not well defined, is the role of neurosteroids in sex differences in 
susceptibility to brain disorders33. For instance, anxiety and depression affect more 
women than men, such as sex differences have been confirmed in the dynamics of 
tobacco smoking and cessation in humans. These differences have been attributed to 
acute and chronic effects of ovarian steroid hormones on nicotinic receptors, although 
findings have not been conclusive.  
In conclusion, experimental and clinical evidences suggest an endogenous role for 
neurosteroids in several neurological and psychiatric conditions such as epilepsy, 
anxiety and depression, with different trends depending on the gender related 
differences, and, indeed, treatment of these neurological diseases and stress-sensitive 
conditions are among the clinical situations in which synthetic neurosteroid analogues 
may have clinical applications.  
The biosynthesis of neurosteroids is controlled by the translocator protein.  
!
1.2 Translocator protein: discovery and characterization  
 
The translocator protein TSPO34, formerly known as peripheral or mitochondrial 
benzodiazepine receptor35, is a 18 kDa protein, consisting in a 169 amino acid sequence, 
mainly located in the outer mitochondrial membrane. First identified in 1977 as a new 
binding site for benzodiazepine diazepam, TSPO has been subsequently studied for its 
ability to bind different molecules, like cholesterol, porphyrins and drugs with various 
affinities.  
TSPO represents an evolutionarily well-conserved family of ubiquitous proteins36, 37; 
although its expression has its higher levels in tissues with steroid synthesizing cells, 
like gonads and ovary, as it is an ubiquitous protein, it has been reported in several 
tissues, like the renal and myocardial, and in hemopoietic and lymphatic cells; is poorly 
expressed in liver. Within the CNS, it is found limited to glia, microglia, the main CNS 
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immune defense, reactive astrocytes and in some neuronal cell types too35. As a 
singular evidence, a small amount of TSPO is also found in the plasma membrane and 
in the cell nucleus34, suggesting potential implications for this receptor in the regulation 
of specific genes expression.  
TSPO plays a crucial role in cells physiology, as remarked by its high sequence 
conservation from bacteria to humans, typical for housekeeping gene, and the evidence 
that a genetic ablation of this receptor results in an embryonic lethal38, 39 suggests it to 
be critically involved in early embryonic developmental functions.  
Since it is a component of the mitochondrial permeability transition pore MPTP, it 
interacts with various proteins, including the 32 kDa voltage-dependent anion channel 
VDAC and the 30 kDa adenine nucleotide translocase ANT40, both essential for the 
complex to work as a functional unit. Moreover, TSPO action is often closely related to 
the activity of steroidogenic acute regulatory protein, StAR41, whose presence seems to 
be needful for steroidogenic cells to move large amounts of cholesterol from the outer 
mitochondrial membrane to the first steroidogenic enzyme, which lies on the matrix side 
of the inner membrane. In summary, the demonstrated TSPO interactions with several 
cytosolic proteins suggests the receptor as a transductor of intracellular signals to 
mitochondria.  
Though a lot of implications regarding the exact physiological role of TSPO have not 
been defined yet, it is currently known its involvement in cholesterol metabolism, 
regulation of steroid biosynthesis42, mitochondrial respiration43, cells apoptosis and 
proliferation40, 44, reactive oxygen species ROS generation45, porphyrins transport and 
biosynthesis of eme group (Fe-protoporphyrin IX)46. 
Being a membrane-bound protein have hindered the X-ray determination of TSPO 
crystal structure, and difficulties are also in expression, purification and stabilization of 
the native structure47. Nevertheless, because of the high homology shown by TSPO 
through different species, relevant investigations have been performed on different 
TSPO homologues, such as the receptor in yeast mitochondrial membranes and 
bacterial homologue tryptophan-rich sensory protein, TspO, of Rhodobacter 
sphaeroides, evaluated as a structural and functional model of the human receptor. 
Rhodobacter sphaeroides TspO primary structure shows 33,5% identity with the aligned 
amino acid sequence of human TSPO (Figure 1.2)48 and this highly significant level of 
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homology makes the TspO a good candidate for biochemical and structural 
investigations. !
Figure 1.3 Comparison of sequence and topology of the human (hTSPO) and bacterial (rsTspO) 
receptor homologues.  !
Electron cryomicroscopy of TspO at 10 Å resolution49 has highlighted a three-
dimensional subunit arrangement composed of five transmembrane α helices forming a 
channel-like monomeric structure. Two monomers are tightly associate to form a 
symmetric dimer, which works as a functional unit (Figure 1.3). The arrangement of 
transmembrane domains of individual TspO subunits indicates the chance of two 
binding sites per dimer which, in turn, allows for the possibility of cooperation in 
substrate transport and potential allosteric modulation.!
Figure 1.4 (A) A view perpendicular to the membrane plane of the TpsO dimer; (B) view 
parallel to the membrane plane of the TspO dimer and after a 40° rotation; (C) view 
perpendicular to the membrane plane; (D) TspO monomer viewed parallel to the membrane 
plane; (E) TspO monomer viewed from the lipid bilayer.!
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It’s currently accepted that TSPO has multiple binding sites, but the nature and function 
of most of them still remain undiscovered. Anyway, the little that is known about this 
topic, has been characterized thanks to a couple of two different synthetic ligands: the 
benzodiazepine derivative Ro5-4864 (7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-
methyl-2H-1,4-benzodiazepin-2-one)50, 51, in vivo agonist52, and the isoquinoline 
carboxamide PK11195 (N-(sec-butyl)-1-(2-chlorophenyl)-N-methylisoquinoline-3-
carboxamide)53, in vivo antagonist52 (Figure 1.4).!
 
Figure 1.5 TSPO synthetic ligands Ro5-4864 (agonist) and PK11195 (antagonist).!
 
It is noteworthy that although these ligands bind to TSPO in a specific manner, they 
have sometimes been shown to produce comparable results, depending upon the 
treatment conditions. More in details, both of these ligands display nano molar affinity 
for the receptor, but while PK11195 binds effectively on TSPO, the binding ability of 
Ro5-4864 requires the cooperation of other mitochondrial components to be completely 
achieved. Especially important, PK11195 behaves as nano molar ligands in both rat (Ki 
of 3.0 nM) and human (Ki of 4.5 nM). Studies of site-directed mutagenesis have 
suggested some particular residues in the first putative loop of TSPO to be essential for 
the binding of Ro5-4864 but not for PK11195; this evidence leads to the consequence 
that the two ligands bind to heterogeneous sites at TSPO, either overlapping or 
allosterically coupled54.  
Although the early observations on PK11195 seemed to indicate a single population of 
saturable sites for this ligand, further studies, performed with [3H]PK11195 on Ehrlich 
tumor cells, revealed two independent binding sites55.    
Recently, studies performed using different TSPO radioligands for PET imaging have 
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highlighted the variability of TSPO binding sites across individuals and tissue type. For 
instance, whereas PBR28 (N-(2-methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide), 
a well known compound with high affinity towards TSPO, radiolabeled with 3H for PET 
analysis, binds competitively to the [3H]PK11195 site in the brains of rhesus monkeys, 
it binds to multiple sites in post mortem human brains, with different affinities across a 
range of patients56. Differences between patients have been measured also for 
[3H]PK11195 in some peripheral tissue, as heart and lungs, correlating to the changes in 
the binding of PBR28 in brain, and this leads to the hypothesis that the variability of 
binding profiles shown by several ligands across patients could derive from differences 
in microglial activation levels, or instead from the concentration at which TSPO ligands 
are evaluated.  
!
1.3 TSPO: the mithocondrial “jack of all trades”  
 
The principal and most characterized function of TSPO is the translocation of 
cholesterol from the cellular citosol, through the mitochondrial membranes, into 
mitochondria, where it can follow its metabolic pathways. The binding site of 
cholesterol at TSPO is located on the carboxy-terminus region, containing a conserved 
cholesterol recognition amino acid consensus sequence [L/V-X(1-5)-Y-X(1-5)-R/K], called 
CRAC57. Though a unique structural determinant for protein interaction with cholesterol 
has not yet been identified, the CRAC sequence is one of the most characterized protein 
domain playing this role, found e.g. in caveolin-1 and in other proteins targeted to lipid 
rafts58, in addition to TSPO59. Remarkably, all other drug ligands bind at the amino-
terminus region, but also other overlapping binding sites have been identified.  
The translocation of cholesterol into the mitochondria happens to be the rate-determinig 
step in the biosynthesis of steroids38, as the binding of this ligand to the receptor enables 
the start of steroidogenesis.  
The first metabolic step, once cholesterol has been translocated in mitochondria, is the 
oxidative cleavage of its side chain, performed by CYP450scc, converting cholesterol 
into pregnenolone; from this intermediate all the others steroids and, as a consequence, 
neurosteroids are originated by several enzymatic reactions, as  previously mentioned.  
Though translocation of cholesterol is the main function of TSPO, this is far to be the 
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last. For instance, other endogenous ligands, endowed with high affinity for this 
receptor, are porphyrins and endozepines60, a family of neuropeptides, deriving from 
proteolytic degradation of a same polypeptide precursor, able to displace 
benzodiazepines from their binding at the GABAA receptor.  
Most generally, being part of the MPTP implicates the involvement of TSPO receptor in 
a series of crucial events, as the regulation of apoptosis and necrosis, modulation of 
cells proliferation, immune regulation61, neuroprotection, injury and inflammatory 
processes. For instance, it has been demonstrated that some TSPO ligands can inhibit 
proliferation in cancer cell lines, showing an accumulation of cells in G1/G0 phase of the 
cell cycle without the possibility to progress to the duplicative phase S and G2/M62. It 
has been suggested that effect on proliferation may be related to the small amount of 
TSPO located inside the cell nucleus, anyway the most interesting point is the 
correlation between concentration of TSPO ligands and the consequent effect on cells 
proliferations: at micro molar concentrations dominates the anti proliferative and 
proapoptotic action, while at nano molar the prevalence is proliferative and 
antiapoptotic effects, through stimulation of mitosis63. Regarding the role of TSPO on 
immune regulation, as it is expressed in microglia and other immune cells64, binding of 
specific ligands on this receptor enables the modulation of cytokine production, 
generating relevant neuroprotective effects at micro molar concentration55, 64.   
Since TSPO has been admitted to play a key role in a variety of physiological and 
pathological conditions65, several studies have been aimed at the willing to better 
understand the molecular mechanisms it is involved in. It’s today an evidence that there 
is a strict correlation between the TSPO expression levels and the progression state of a 
number of diseases66. More in detail, it results upregulated in a number of pathologies 
like particular type of cancers67, brain injury and inflammation and several 
neurodegenerative disorders60, such as Alzheimer’s68, 69, Huntington’s70 and 
Parkinson’s71 disease, multiple and amyotrophic lateral sclerosis72, dementias73. As a 
matter of fact, it had been widely demonstrated by a series of studies that TSPO is 
consistently overexpressed in highly invasive human breast cancer cells and that the 
strength of cancer cells in origin tumors is directly related to the amount of TSPO 
within these cells74, 75. At the same time, evaluation of TSPO levels in human ovary76, 
colon77, prostate77 and brain cancer cells, shows a consistent increase in concentration, 
comparing with healthy tissues. Notably, positive correlation between TSPO expression 
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levels and the metastatic potential of different human tumor, as breast cancer74, 75, 
gliomas78 and astrocytomas79, has been demonstrated, reinforcing the hypothesis of a 
role for this receptor in carcinogenesis, though its specific involvement is far to be 
cleared up.  
Concerning microglia, the mechanisms controlling TSPO expression still remain 
unclear. It is possible that the increase in its levels may be merely due to a general 
increase in the microglial cells number, or that TSPO increases within each microglial 
cell, as it becomes activated. As an instance, in Leydig cells, the activation by cytokines 
leads to the raising of TSPO mRNA levels, proving that the enhancement in TSPO 
concentration is linked to transcriptional events.  
At the state of the art, several studies have shown evidences that cholesterol plays a 
certain role in the progression of a number of pathologies and cancers, as it is 
accumulated at intracellular level; in fact, in animal models, cholesterol synthesis 
inhibitors, such as statins80, are selective for cancer cells, where they carry out the 
inhibition of cellular growth and motility. Another evidence is offered by numerous 
epidemiological studies which highlight the probability that a diet frequently rich in fats 
might promote cancer onset and growth. As TSPO is the intracellular receptor to whom 
cholesterol binds, this can explain at least its first implication in some pathological 
conditions.  
As noticed before, the regulation of TSPO expression happens to be significantly 
increased also in neurological injury81, inflammation82 and degeneration. If in healthy 
central nervous system, TSPO is expressed in low concentration limited to glia and 
some type of neurons, its expression dramatically increase in pathological conditions. At 
the same time, in PNS (peripheral nervous system), TSPO levels result transiently 
increased in response to nerve injury, in dorsal root ganglia sensory neurons, in 
Schwann cells and in macrophages, right at the site of injury83, 84.  
The principal physiological effects of TSPO mediated neuroprotection and 
neurogenesis, assessed by different works, have been so far accounted for by the 
stimulation of steroids and neurosteroids biosynthesis and activity85. As an instance, 
allopregnanolone has been recently studied for its ability to promote neuroregeneration 
in an Alzheimer’s disease mouse model86. This neurosteroid, administered in chronic 
exogenous treatment regimen, has been demonstrated to induce neurogenesis correlated 
with restoration of learning and memory function; its efficacy was comparable also 
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when administered in aged normal mice, as endogenous allopregnanolone declines with 
age, as well as in neurodegeneration.  
The importance of TSPO in regenerative processes, concerning nervous system, is 
supported by the evidence that its strongly upregulated expression, saw after injury and 
inflammation, returns to low control values only when nerve regeneration is completed.  
Moreover, sex steroids promote neural protection and repair; after neurotrauma, for 
example, locally produced estrogens reduce neurodegeneration in zebra finch 
cerebellum by suppressing different steps of the apoptotic pathways87. Obviously, sex 
steroidogenesis is started thanks to TSPO translocation of cholesterol, as well as the 
involvement of the StAR protein, and once again this accounts for the strategic role 
played by the receptor in multiple CNS and PNS physiological and pathological events.  
Finally, one more interesting point researchers are focusing on is TSPO involvement in 
the transport of protoporphyrins, which are needed as precursors in the biosynthetic 
pathway of eme group, carried out both in cytoplasm and mitochondria. A study on 
zebrafish Tspo has demonstrated that this protein modulates in vivo primitive 
erythropoiesis88. Moreover, the lack of functionality of Tspo, both genetically and 
pharmacologically induced, resulted in embryos with specific erythropoietic cell 
depletion88, which is not due to the invalidation of cholesterol binding site and such an 
evidence highlights that the essential in vivo role of this receptor is far to be only 
accounted for this, although important, function.  
!
1.4 The raise of pharmaceutical interest  
 
As far as told until now, the intense pharmaceutic interest, raised in the last two decades, 
in developing specific ligands for TSPO appears perfectly justified. The research of 
new potent and selective molecules able to bind the receptor has been guided through a 
number of compounds, belonging to various chemical classes, as 
pyrrolobenzodiazepines, phenoxyphenylacetamide derivatives, indolo derivatives and 
imidazopyridines. Most of these ligands have been designed starting from selective 
CBR ligands, already deeply investigated in the previous years, which were structurally 
modified in order to shift their affinity towards TSPO.  
Indeed, at first, the ligands chosen for the evaluation of the new receptor characteristics 
"12
Introduction
were benzodiazepines themselves, not taking count of the lack of specificity of most of 
these compounds. As an example, Diazepam, which is able to bind, with different 
affinity, both GABAA and TSPO; its ability to bind the two receptors, didn’t allow to 
define the particular chemical properties required for the specific targeting of TSPO. 
Unlikely, Clonazepam, a Diazepam analogue with binding selectivity for GABAA, 
didn’t show any affinity for TSPO. Another remarkable benzodiazepine derivative was 
the already mentioned Ro5-4864, a ligand for both the peripheral and central nervous 
system benzodiazepine binding sites, acting as an in vivo TSPO agonist52. Afterwards, 
with the aim to develop new TSPO ligands, in 1983 were described a series of 
compounds called isoquinoline carboxamides which, although being structurally 
different from benzodiazepines, had greater specificity for the TSPO than for the 
GABAA receptors89. To this family belongs the PK1119553, previously mentioned as in 
vivo TSPO antagonist52, deeply investigated in the past years with the aim to better 
understand the receptor structure and the physiological effects induced by its action. The 
PK11195 displaced [3H]Ro5-4864 from its binding sites in all the organs. Subsequently, 
in 2001 as an extension of the SAR (structure-activity relationship) on TSPO ligands 
structurally related to PK11195, Anzini et al.90 performed the design, by means of 
computational approach, of a series of carboxamide derivatives bearing differently 
substituted planar aromatic or heteroaromatic systems. The main aim was to get further 
information on the topological requisites of the carbonyl and aromatic moieties for 
interaction with the TSPO.  
More recently, several new synthetic ligands have been developed and carefully 
investigated for their binding selectivity for TSPO as, to name but a few, PK14105 (N-
(sec-butyl)-1-(2-fluoro-5-nitrophenyl)-N-methylisoquinoline-3-carboxamide), 
FGIN-1-27 (2-hexyl-indole-3-acetamide), FEAC (N-benzyl-N-ethyl-2-(7,8-dihydro-7-
(2-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl)acetamide), FEDAC (N-benzyl-N-
methyl-2-(7,8-dihydro-7-(2-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl)acetamide), 
AC-5216 (N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-
yl)acetamide) and DAC (N-benzyl-N-methyl-2-(7-methyl-8-oxo-2-phenyl-7,8-
dihydro-9H-purin-9-yl)acetamide.  
As a consequence of the number of TSPO ligands belonging to different chemical 
families, yielding results of high affinity and selectivity, several pharmacophore models 
have been proposed, depending on the different SAR (structure-activity relationship) 
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data, despite the topology of the TSPO binding cleft is still not completely defined. 
Notably, a pharmacophore model widely accepted is the one derived from the binding 
evaluation of imidazopyridine and pyrrolo[3,4-b]quinoline derivatives. Imidazopyridine 
derivatives are a family of compounds obtained by modifications of the progenitor 
Alpidem (6-chloro-2-(4-chloro-phenyl)-N,N-dipropylimidazo[1,2-a]pyridine-3-
acetamide)91, an anxiolytic drug developed by Synthélabo, approved for marketing in 
France in 1991 and withdrawn from the French market by 1994 as a consequence of 
several cases of severe and even lethal side effects92. Alpidem was known to bind both 
CBR and TSPO with nanomolar affinity, with Ki respectively 1-28 nM and 0.5-7 nM. 
The anxiolytic and anticonvulsivant effects of Alpidem were accounted to a double 
mechanism of action, one directly mediated by its interaction with CBR and the other 
elicited with neurosteroids production, obtained as an indirect consequence of the 
interaction with TSPO. A wide SAR study, performed in 1977, on Alpidem and a series 
of 2-phenyl-imidazo[1,2-a]pyridine derivatives, showing different degrees of affinity 
and selectivity for TSPO with respect to CBR, led to the proposal of a TSPO 
pharmacophore model whose schematic representation includes three regions: a freely 
rotating aromatic ring region (FRA), an electron rich zone (δ1), a planar aromatic region 
(PAR) and a lipophilic area (LA). The same model seems to be working for CBR too, 
with the exception of an out plane region (OPR) in place of the LA. The different zones 
were termed using the nomenclature proposed by Wermuth and Bourguignon in 198793.  
Hereafter, pursuing the goal to evaluate the effects of structural modifications on the 
amide nitrogen at both CBR and TSPO, Trapani and coworkers synthesized a new 
family of compounds, the imidazopyridineacetamides94. Their research was taking 
advantage also of the recent results obtained by new SAR studies of different class of 
ligands and further informations deriving from molecular biology experiments90. This 
relevant amount of data allowed to highlight three key structural features for the 
achievement of ligands with high affinity toward TSPO: a conveniently located and 
oriented C(=O)N functional group, the involvement of lipophilic substituents attached 
to this C(=O)N group and the presence of an aromatic or heteroaromatic system with a 
pendant phenyl ring. Moreover, a unique 3D model of interaction between endogenous 
and synthetic ligands and TSPO had been developed in 200095. This model, based on 
TSPO primary sequence, describes the presence of two lipophilic regions (L1 and L3), 
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one polar residue (H2), shown to be essential for the interaction with TSPO and one 
more lipophilic portion (L4) playing a direct modulation in receptor binding. Receptor 
mapping and receptor fitting approaches suggested in particular three amino acid 
residues Ser41, Trp107, and Trp161 as the key elements for ligand interaction, due to 
their involvement in a hydrogen bond with the amide carbonyl group (Ser41 residue) 
and in hydrophobic interactions with the groups bounded to this amide group (Trp107 
and Trp161 residues).  
!
1.5 Pyrazolo[1,5-a]pyrimidineacetamides: a breakthrough in developing TSPO 
ligands  
 
Relating to the wide investigated family of imidazopyridines, in 2001 Selleri et al. 
developed a series of new compounds, shaped as azaisosters of Alpidem, based on the 
clear knowledge that introduction of proper substituents and opportune modifications on 
the acetamido[1,2-a]pyrimidine nucleus of Alpidem leads to compounds with improved 
TSPO affinity and selectivity vs CBR. These new molecules were formed on the basis 
of a N,N-diethyl-(2-aryl)pyrazolo [1,5-a]pyrimidin-3-ylacetamide96.  
At first, maintaining fixed the tertiary acetamide moiety at position 3, as previously state 
crucial for the formation of the hydrogen bond necessary to achieve the binding to the 
target protein, positions 5 and 7 of the central scaffold and para-substitution at the 2-
phenyl ring were carefully investigated. From the corresponding SAR data it turned out 
that the presence of small lipophilic substituents (CH3) in 5 or 7 didn’t entail selectivity, 
suggesting a tolerance of these groups into both the lipophilic pockets of CBR and 
TSPO. On the other hand, substitutions at position 6, corresponding to position 7 in the 
imidazopyridine nucleus of Alpidem, as well as the contemporary presence of two or 
more substituents (CH3 or more steric demanding phenyl group) on the fused pyrimidine 
ring, allowed the obtainment of derivatives with high affinity and selectivity for TSPO. 
Likewise, the choice of substituents such as Cl, F, CH3, OCH3 in para at the 2-phenyl 
ring results in a sensitive increase in TSPO affinity and selectivity.  
In a further study of 2005, the same authors explore the position 3, on the fused 
aromatic rings, to clarify the role of the amide moiety and the principal structural 
features of the substituents on the amide nitrogen97. Choosing the 2-(5,7-dimethyl-2-(p-
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tolyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide as lead compound, the 
authors performed a series of further modifications to this scaffold, keeping fixed the 2-
phenyl ring and the two methyl groups at positions 5 and 7, while switching the 
substituents on the amide nitrogen between different alkyl and aryl-alkyl chains (CBR, 
central benzodiazepine receptor, and TSPO affinity of different pyrazolopyrimidine 
derivatives are  shown in Figure 1.6). !
!
 
Figure 1.6 CBR and TSPO affinity of pyrazolopyrimide derivatives 145-157.  
 
 
Analyzing data of binding tests, the presence of phenyl ring on the amide nitrogen 
emerged as a positive contribute in increasing the TSPO affinity, while the introduction 
of chains between the amide nitrogen and the aromatic ring involved in a moderate 
reduction of this parameter. Concerning the alkyl substituents on the amide nitrogen 
group, the most appealing observation resulted the importance of its length, with the 
three atoms linear chain performing the best affinity, with a Ki value of 0.8 nM. 
Otherwise, ramifications of the chain or introduction of cyclic amines on it worsened 
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the affinity of the compounds.  
Notably, in the whole series of pyrazolo[1,5-a]pyrimidines, the high affinity and binding 
potency appeared to be assured by the methylene linker between the pyrazolopyrimidine 
nucleus. In fact, the removal of this methyl group from the chain, as well as the 
substitution of the amide group with the ester function, led to compounds with a 
substantial decrease in binding capability.  
The most promising compounds, in terms of affinity and selectivity, were also tested for 
their ability in stimulating steroidogenesis. The tests were performed by 
radioimmunoassay in C6 rat glioma cells. Some of the compounds tested showed a 
capability in stimulating steroid biosynthesis comparable to that of Ro5-4864 and 
PK11195. At the same time, three molecules showing high affinity properties were not 
able at all to induce steroidogenesis, confirming the previous hypothesis that no 
correlation between affinity and steroidogenic activity can be declared for TSPO ligands 
and introducing the necessity to identify the specific features of TSPO agonists and 
antagonists.  
!
1.6 TSPO and imaging: the odd (but successful) couple 
 
As above mentioned, an elevated TSPO expression is found in several disease states, 
including neuroinflammation, neurologic disorders, such as Alzheimer’s68, 69, 
Huntington’s70 and Parkinson’s71 disease, as well as cancers of the breast74, prostate98, 
oral cavity99, colon rectal67, liver100 and brain78, 79.  
Given that most of these pathologies show poor prognosis, constantly increasing with 
their staging, it’s obviously desirable to find specific biomarkers, whose presence or 
quantified concentration leads to an early and exact diagnosis. For these reasons, TSPO 
has become over the years a promising biological target for diagnostic purposes in the 
imaging of neurological disorders or cancer spread, and this relevance as a biomarker 
has been fueled mainly by PET (positron emission tomography) studies101, 102.  
With this aim, several compounds, previously tested for their binding ability against 
TSPO, have been radiolabeled and screened as PET radio tracers. The first to be 
synthesized was [11C]PK11195103, clinically used since 1986 (Figure 1.7).  
!
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Figure 1.7 11C labeling of the PK11195 by means of a methylation reaction.!
 
As for the non radiolabeled molecules, the isoquinoline carboxamide [11C]PK11195 still 
represents a standard for TSPO PET radioligands, but in fact it shows critical limitations 
for PET imaging, such as a poor signal-to-noise ratio and low brain penetration (not 
taking account of the short half life of 11C, with a t1/2 of 20.4 minutes). Such drawbacks 
have encouraged the development of new radiotracers, in the willing to improve these 
crucial parameters. For instance, in the phenoxyphenyl acetamide class, [11C]DAA1106 
([11C]-N-(2,5-dimethoxybenzyl)-N-(4-fluoro-2-phenoxyphenyl)-acetamide)104 and its 
fluorinated analogue, [18F]FEDAA1106 ([18F]-N-(5-fluoro-2-phenoxyphenyl)-N-(2-(2-
fluoroethoxy)-5-methoxybenzyl) acetamide)105, the latter labeled with the longer half 
lived positron emitter 18F (t1/2 of 109.8 minutes), turned out as better radioligands 
compared to [11C]PK11195, with an improved signal-to-noise ratio and, indeed, 
showing better imaging results.  
To the same chemical family of [11C]DAA1106 and [18F]FEDAA1106 belong 
[18F]PBR06 ([18F]-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline)106, 
bearing the 18F at the N-acyl function. This radiolabeled compound has been recently 
reported as high affinity tracer for both brain tumors visualization and TSPO 
quantification in tumor and healthy tissues107. 
Subsequently, from [18F]PBR06, new compounds were derived, featuring a pyridine 
motif. In particular, in 2007 was developed [11C]PBR28 ([methyl-11C]N-acetyl-N-(2-
methoxybenzyl)-2-phenoxy-5-pyridinamine)108, which gave promising imaging results 
in monkeys and rats and is still widely used, such as its fluorinated analogue 6-
[18F]fluoro-PBR28.  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As above described for TSPO non labeled ligands, bioisosteric derivatives of Alpidem 
have been projected as specific tracers to target the receptor. Within this class, 
[11C]DPA-713 (N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-
a]pyrimidin-3-yl]acetamide)109 is one of the most important and investigated compound. 
In 2007, Boutin et al. performed PET studies on a rat model of neuroinflammation, 
induced by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), using both 
[11C]PK11195 and [11C]DPA-713 and comparing the differences in terms of binding 
ability and image quality110. The AMPA lesion gave rise to a well defined TSPO rich 
lesion that could be easily and similarly visualized using appropriate TSPO tracers. The 
results proved [11C]DPA-713 to have a higher signal-to-noise ratio than [11C]PK11195 
because of a lower level of unspecific binding, with high probability due to the lower 
lipophilicity of [11C]DPA-713. The latter showed also to image better the contrast 
between healthy and damaged brain area, though in the ipsilateral side its uptake was 
significantly lower than [11C]PK11195. 
In 2008, as a result of a project led in collaboration with our group, James reported the 
synthesis, radiofluorination and pharmacologic evaluation of a new TSPO ligand, 
belonging to the same class of [11C]DPA-713, [18F]DPA-714 (N,N-diethyl-2-(2-(4-
(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide)111. 
PET studies in rats and baboons confirmed the view of this compound as a specific 
ligand of TSPO, endowed of high selectivity and good pharmacokinetics properties, as 
well as low toxicity. Even though [18F]DPA-714 has a slightly higher lipophilicity than 
[11C]DPA-713 which, as seen, can lead to an increase of non specific binding, this 
compound allows longer imaging protocols and, as a consequence, can be considered as 
a more suitable radiotracer (structures of both cold and labeled [11C]DPA-713 and 
[18F]DPA-714 are shown in Figure 1.8).  
Afterwards, in 2009, Chauveau et al. related of a new comparative PET study, in the 
same AMPA neuroinflammation rat model above mentioned, between [11C]PK11195, 
[11C]DPA-713 and [18F]DPA-714, and this direct comparison proposed the 
[18F]DPA-714 as the overall most promising PET radiotracers for TSPO imaging for 
image definition, uptake and biodistribution112, not to mention the ease of labeling with 
18F. !
!
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Figure 1.8 Labeling and structure of [11C]DPA-713 and [18F]DPA-714 radiotracers.!
 
Since it has been demonstrated that [18F]DPA-714 rapidly and extensively undergoes in 
vivo metabolism in animal models (rats and baboons), in particular for the cleavage of 
fluoroethoxy side chain which leads to the formation of small radio metabolites entering 
the brain and lowering PET imaging quality, a recent study (2014) has developed a 
DPA-714 analogue, CfO-DPA-714. This compound is obtained replacing the DPA-714 
oxygen atom bridging the phenyl ring and the fluoroethyl motif with a methylene group. 
The corresponding 18F labeled version [18F]CfO-DPA-714 has been recently synthesized 
and is currently studied for in vivo evaluation113.  
As a further advancement, in 2013 has been published an interesting article about the 
implementation of DPA-713 as part of a new probe for magnetic resonance imaging 
(MRI)114. This probe consists of two sections, linked by a six carbon atom chain: the 
TSPO ligand DPA-713 and a mono amide DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) cage. The gadolinium (Gd) dedicated 
DOTA chelator represents the magnetic resonance imaging reporter, while the DPA-713 
is the part of the conjugate designated to target the TSPO receptor.  
Indeed, such a conjugate shows different bioavailability and biodistribution properties 
than DPA-713; for instance, the good hydrophilicity of the metal chelate makes DPA-
C6-(Gd)DOTAMA soluble in water, so the authors decided to load the probe to a large 
carrier, such as a liposome, with the aim to increase its lifetime in blood. Considering 
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the promising availability of the whole complex, including the liposome it is loaded to, 
and the consequently increased half life in blood stream, the authors suggest future in 
vivo studies, encouraging the search of new slow releasing MRI targeting agents.   !
!
Though what it has been here written until now represents only a brief overview of the 
whole subject, it should be enough to deeply understand how important and desirable is 
the comprehension of the molecular mechanisms of TSPO function and regulation, as 
well as how challenging and appealing is, for medicinal chemistry, the fine tuning of 
specific ligands developed for both therapeutic and diagnostic purposes. !
!
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2. AIM OF THE THESIS!!
Considering the broad spectrum of actions demonstrated and suggested for TSPO, 
researchers interest has been focused both on the therapeutic and, more recently, with 
the spread of imaging techniques, the diagnostic goal. !
In regard of the first purpose, we can characterize applications in three main paths, that 
is control of the inflammatory response after injury, cancer regression and axonal 
regeneration.  
The latter aim appears especially appealing, as there is no currently efficient treatment 
for enhancing axonal regeneration, including elongation speed and functional 
reinnervation.!
As local production of neurosteroids has been demonstrated to confer neuroprotection in 
CNS, the chance of modulating TSPO activity with pharmacological ligands, in order to 
start or enhance the production of neurosteroids locally in the injured CNS, should 
result in attenuating several neuroinflammation and neurodegeneration pathologies.!
A recent paper from Daugherty D. and coworkers (2013) examined the effects of 
etifoxine, a clinically available anxiolytic drug, in the development and progression of 
mouse EAE (experimental autoimmune encephalomyelitis), a model for multiple 
sclerosis115. Results showed that etifoxine modulation of TSPO attenuated EAE severity 
when administered before the development of clinical signs and improved symptomatic 
recovery when administered at the peak of the disease, suggesting TSPO ligands to be a 
potential new therapeutic option for multiple sclerosis, avoiding the detrimental side 
effects of long term direct use of steroids, and leaving an open door for therapeutic 
approaches to other neurodegenerative diseases.  
The first aim of this work was to synthesize a small number of compounds, belonging to 
the 2-arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides series, to be investigated for their 
binding affinity towards TSPO and for their ability to induce the endogenous production 
of pregnenolone (the first steroid deriving from cholesterol metabolism) in C6 cells, a 
cellular line derived from rat glioma.  
The lead compound that we chose as reference for the new series was the PBR 136, 4-
(3-(2-(diethylamino)-2-oxoehtyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl 
benzoate; this molecule was beforehand obtained, in high percentage (80%), as 
secondary product in the first synthesis of PBR 137, 2-(2-(4-
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(difluoromethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-
diethylacetamide, and, sent to the binding test, by surprise tuned out to have a very low 
Ki (0.02 nM). Despite its Ki, the steroidogenesis assay showed a pregnenolone 
increment of about + 25.55% vs controls.  
Anyway, encouraged by the binding result of PBR 136 and by the will of trying to 
understand wether a compound can act as a TSPO agonist or antagonist, we decided 
first of all to obtain PBR 136 directly as the desired goal of the synthetic pathway, by 
the way performing an optimization of some critical reaction steps, and then to 
investigate its analogues, joint by the presence of ester group at the phenolic -OH of the 
aromatic ring in position 2 of the pyrazolo[1,5-a]pyrimidine nucleus.   
Thanks to a collaboration with Prof. Michael Kassiou, University of Sidney, Australia, 
we were able to test two other series of TSPO ligands, the sb, to which belong 
analogues of our PBR 136 but with an ether, instead of an ester, group, and the Raj, 
composed of different structure bearing an indole-2-carboxamide core. The availability 
of a wide number of different compounds to screen both by binding test and 
pregnenolone assay, suggested us the idea to perform a future SAR study statistically 
sizable.!
Regarding the other principal field of interest of this project, the developing of TSPO 
radiotracers as tools for the biomedical imaging, blasted in the last 10 years, boosted by 
the strong evidence of an increasing in TSPO expression levels, directly linked with a 
pathological event occurrence, as neuroinflammation or neurodegeneration, right at the 
site of injury. Since this correlation was demonstrated, the new researchers purpose has 
been to synthesize, label and test new molecules endowed not only with high affinity to 
TSPO but even low toxicity profile and proper bioavailability and distribution.  
As previously said, within the class of bioisosteric derivatives of Alpidem previously 
synthesize in our laboratories, [11C]DPA-713 and [18F]DPA-714111, were labeled and 
extensively tested as PET radiotracers on mouse and baboons by Prof. Kassiou staff, as 
a part of the above mentioned collaboration between the two groups, giving promising 
results. Due to their binding ability, image quality and lower level of unspecific binding, 
at the state of the art these two molecules have been both tested on human, showing 
good pharmacokinetic properties, and still clinical trials with [18F]DPA-714 are in 
progress.  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These strong results, both with new recent papers based on the use of DPA-713 as a part 
of magnetic resonance probe114, further reinforces our aim to promote TSPO ligands as 
carriers of radionuclides for diagnostic (and therapeutic) purposes. This time we decided 
to synthesize a radioconjugate of a 2-aryl substituted pyrazolo[1,5-a]pyrimidin-3-yl 
acetamides (already validated as TSPO ligand) linked by a PEG spacer to a chelating 
complex, to be subsequently labeled. At the first time we decided to perform the 
synthesis with two different PEG, one of intermediate molecular weight (3000) and the 
other of low molecular weight (149,19), attracted by the possibility to split them to 
different applications; hereafter, as we had to choose one for the labeling trials, we 
preferred to focus on the second one, which was the most simple to handle. Anyway, if 
all the tests on this conjugate will be successful, our aim will be to subsequently 
investigate the one of higher molecular weight as a diagnostic/therapeutic agent carried 
by the lymphatic system for the identification of metastasis (as TSPO has been assessed 
to be over expressed more and more with the malignancy spread in several cancer type).   
The chosen chelating group in both cases was DOTA (tetraazacyclododecane tetraacetic 
acid), even if, once optimized the synthesis, the radioconjugate could be obtained with a 
range of specific chelating groups tailored to the complexation properties of each 
radiometal and non-radiometal.  
Back to the selected conjugate, we decided to perform the labeling trials with 111In, as a 
first approach, to determine the best radiochemistry procedure. Once optimized the 111In 
labeling, we thought that performing other trials, this time with the 68Ga isotope, could 
give more completeness to our project. In fact, together with the better signal to noise 
ratio of 68Ga with respect to 111In, it is sometimes used as a surrogate of 90Y, since they 
have a very similar radiochemistry. In this way it is possible to take advantage of the 
ease of using 68Ga for preclinical and clinical studies, and eventually replace it with 90Y 
if a therapeutic approach is requested.  
 It goes without saying that the ultimate target of this work was to test the radiolabeled 
compound in a wild type mouse and in a neurodegenerative mouse model, to take 
account of the possible metabolization, biodistribution and toxicity and the effective 
ability of the conjugate to be a novel, predictive imaging biomarker. The selected 
imagine technique for the study was PET, which is today widely used for the sensitivity 
and high quality results of images as they are better than those achievable by MRI and 
CT (computed tomography) as an example in brain tumors, like gliomas, reason why 
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there is a considerable need to develop and validate selective radiotracers (wishing both 
with improved new imaging techniques).  
Although the time required by the in vivo tests have not yet made it possible to achieve 
them, they will be performed before long. 
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3. RESULTS!
!
3.1 Optimization of the classical synthetic pathway  
!
As already known, the first aim of our work was to obtain compound PBR 136 (4-(3-(2-
(diethylamino)-2-oxoehtyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl 
benzoate, Figure 3.1) as the final, desired, product of the synthetic pathway, since 
previously it had been obtained just as a side product during the synthesis of a different 
compound. !
!
!
!
!
 
!
!
!
!
Figure 3.1 Chemical structure of the lead compound PBR 136.!
!
To obtain the precursor of PBR 136, that is PBR 129 (N,N-diethyl-2-(2-(4-
hydroxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide), we chose to 
follow the synthetic strategy (displayed in Figure 3.1) already described in earlier works 
from our group (Selleri et. al., 2001)96. Concerning this point, we thought about the 
possibility to perform at least a slight optimization of some of the most critical steps of 
this synthetic strategy, without changing the nature and sequence of the reactions, but 
trying to influence their duration and yield. In addition, we decided to synthesize 5-(4-
methoxyphenyl)isoxazole as the precursor to achieve, after opening of the isoxazole 
ring by means of a sodium alcoholate solution, the 3-(4-methoxyphenyl)-3-
oxopropanenitrile (compound 3 in Figure 3.2 below), unlike the synthesis previously 
reported in the article. This intermediate step, which doesn’t invalidate the obtainment 
in high percentage yield of the desired compound, was originally studied by Prof. Sarti 
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Fantoni at the University of Florence, and turned out to be a valid option whether the 
commercial 3-(4-methoxyphenyl)-3-oxopropanenitrile is not available. !
!!!!!!!!!!!!!!!!!!
Figure 3.2 General synthetic procedure for the attainment of compounds 8,9; 8F-12F. The 
abbreviation MW indicates the microwave assisted steps. !
!
Also, the direct attainment of the latter compound by reaction of the relative ester with 
CH3CN and NaH was not possible, as the presence in p-position of the methoxy group 
leaded to a left shift in the reaction balance, as previously noticed by my research group. 
As sometime reported by literature, during the attainment of 5-(4-
methoxyphenyl)isoxazole, we obtained, as side product in reasonable proportion, a 
precipitate not soluble in EtOH, which showed a NMR signal compatible with 2-(4-
methoxyphenyl)-2,5-dihydroisoxazole; its formation, at first glance, seemed to be 
temperature-depending. !
Concerning the functionalization of position 3 with the N,N-diethylacetamide chain, 
this one is the most critical step of the whole synthetic process. According to literature 
previously reported by my group97, it is better to insert this chain before the closure that 
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leads to the aminopyrazole core; for this reason, in the article above mentioned, the 
proper aroylacetonitriles were reacted in alkaline medium with N,N-
diethylchloroacetamide to afford the deriving N,N-diethylbutanamides. However, as 
reported, the desired product was obtained after two days of reflux and together with 
tars and impurities; this event, both with the fact that, in my case, the 3-cyano-N,N-
diethyl-4-(4-methoxyphenoyl)-4-oxobutanamide (compound 4) had an oily texture, 
complicated the final purification, making flash column chromatography mandatory. !
Taking into account these difficulties, to the left of a classic synthetic approach, we 
chose to experiment a couple of new strategies in the willing to optimize the obtainment 
of 3-cyano-N,N-diethyl-4-(4-methoxyphenoyl)-4-oxobutanamide, without overturning 
the whole synthetic pathway already developed.!
The first attempt was to make 3-(4-methoxyphenyl)-3-oxopropanenitrile react with 2-
iodoacetic acid, heating to reflux in EtOH with LiOH, to achieve the 3-cyano-4-(4-
methoxyphenyl)-4-oxobutanoic acid, to be subsequently converted in the corresponding 
amide. This reaction happened to be more favorable than the one that led directly to the 
formation of 3-cyano-N,N-diethyl-4-(4-methoxyphenoyl)-4-oxobutanamide, in terms of 
duration. Anyway, the yield after chromatography purification and closure with 
hydrazine monohydrate, to achieve 2-(5-amino-3-(4-methoxyphenyl)-1H-pyrazol-4-
yl)acetic acid after a second purification on silica gel, led to a lack of pure compound, 
because of the amount of side products and impurities still taking origin from the 
reaction. !
Considering the point, we decided to go back to the direct formation of the 
oxobutanamide, exploring the possibility to optimize the reaction yield and/or duration 
by means of microwave radiation. We followed this way encouraged by a paper of 
Tang116 (2010), discussing the implementation of microwave in the obtainment of 
similar products, so building on from this article we decided to work our way to the best 
matching of usable solvents and methods and timing of radiation. !
At the beginning, we started with the formation of compound 4 by reaction of 3-(4- 
methoxyphenyl)-3-oxopropanenitrile and 2-chloro-N,N-diethylacetamide in 80% EtOH, 
KI and NaOH. We performed different tests, irradiating with microwave three different 
vessels respectively to a temperature of 65 °C for 60 min, 80 °C for 40 min, 100 °C for 
25 min, taking only a fixed temperature value on the instrument (Explorer 48, CEM), 
without setting up the potency. As a first result, after the work up of the three reactions 
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and their purification by flash chromatography, the two vessels with the higher 
temperature were the best in terms of yield (about 70%), but the reaction carried out at 
100 °C seemed to have more impurities. So we prefer to choose the 80 °C for 40 min 
protocol (about 30 W of potency), even if it had to be carried out for more time. !
With the same approach of the three vessels, we investigate then the reaction of 
compound 4 in EtOH with hydrazine monohydrate and with a catalytic amount of acetic 
acid, same reagents as for the classic synthetic strategy. We performed the reaction at 70 
°C for 60 min, 90 °C for 40 min and 110 °C for 20 min. As for the synthesis above, the 
best results in terms of final yield (42%) of compound 5 were achieved by the 90 °C for 
40 min protocol still with no fixed potency (about 35 W), still confirming the key role of 
temperature. !
Concerning the synthesis of compounds 6 and 6F, this step, involving in one case the 
reaction between compound 5 and 2,4-pentanedione and in the other with 1,1,1,5,5,5-
hexafluoropentane-2,4-dione, usually carried out in EtOH heated to reflux, had an 
outcome rather satisfying in the classic synthetic strategy (about 80% yield for 6 and 
60% yield for 6F). Anyway, we decided to try to achieve 6F performing a microwave 
assisted reaction, particularly to try to reduce the duration of the classic synthetic 
reaction (about 5 h). After several attempts, we found that carrying out the reaction in 
DMF with a power cycle protocol gave the best results. During the power cycle mode, 
the instrument perform a number of short cycle of irradiation and consecutive cooling of 
the reaction mixture. This protocol is sometime found in literature to promote 
cyclization or closure of organic molecules. In our case, we chose 300 cycles with a 
maximum potency of 300 W, with a range of temperature between 115 °C, lower limit, 
and 130 °C, upper limit. The duration of the whole protocol was less than 2 h and, after 
the work up and the purification via flash chromatography, the final yield was of 70% 
(instead of 60% mentioned above), so we reached a reasonable optimization in the 
synthesis of compound 6F.  
The de-methylation of compounds 6 (to obtain PBR 129, 7 in reaction pathway) and 6F 
(to obtain PBR 127, 7F in reaction pathway) was carried out directly pouring HBr (48% 
in H2O) in the flask containing the dry compound and well heating to reflux overnight in 
an oil bath. This reaction, even if it had to be carried out overnight, enabled after very 
simple work up to purify the mixture and to obtain the desired product with a good yield 
of about 65% in both cases. !
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3.2 Direct synthesis of PBR 136 and a small series of analogues  
 
Once optimized the achievement of the two precursor PBR 129 and PBR 127, the next 
step was to synthesize directly the PBR 136, as previously said. For this reason, we 
chose at first to proceed in one of the 
most classic way, that is making the 
proper precursor react with the 
selected acyl chloride in dry pyridine, 
stirred at room temperature and under 
N2 atmosphere. In the case of PBR 
136, we made PBR 129 react with 
benzoyl chloride; unfortunately, even 
if the NMR spectrum of the mixture 
showed that the reaction was 
proceeding, the subsequent work up, 
involving the use of HCl (tested 6 M, 
3 M and 1 M in three distinct 
attempts), brought principally back to 
the initial phenolic compound.  
The ester hydrolysis in presence of H+ is usually due to the presence of H2O, so as at a 
first time we used fresh pyridine dried on molecular sieves, we performed another 
synthesis with anhydrous pyridine (obtained after distillation), under N2 atmosphere. 
However, after the new work up with fresh HCl, we found that the result was the same.  
So far, we decided to change the reaction conditions, as we were focused on the 
obtainment of the products to be subsequently tested, so we moved to the esterification 
of PBR 129 and benzoyl chloride with triethylamine in dry CH2Cl2, under N2 
atmosphere, stirred at room temperature. This attempt happened to be successful; then, 
after filtering the solution, washing with a 1 m solution of KOH, extracting it in EtOAc 
and drying the organic phase under vacuum, we performed a purification via flash 
chromatography to obtain PBR 136, the desired product, as light brown crystals (about 
50% yield).  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Figure 3.3 Ester derivatives of PBR 127 and 129. 
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After the attainment of PBR 136, our following purpose was to synthesize a small series 
of ester analogues, so we prepared, with the same procedure already specified, the 
compounds reported in the grid above (Figure 3.3).   
We built this small series with the aim to test these compounds for their affinity vs 
TSPO receptor and for their ability to provoke a biological response when interacting 
with it, so to analyze their pharmacological profile. Spectra of the compounds from 8F 
to 12F are shown below (A, B, C, D, E in Figure 3.4). !
!
!
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Figure 3.4 1H-NMR in CDCl3 of compounds 8F-12F, respectively A-E. The structure of 
each analyzed compound is reported next to the related spectrum. Spectra A, C and E 
were obtained with a 400 MHz instrument; B and E with a 200 MHz instrument.!
!
3.3 Binding tests and steroidogenesis assay: the biological challenge 
 
To asses the affinity of a compound toward a receptor, it is necessary to test it with a 
binding assay. We went to Pisa, among the group of Prof.ssa C. Martini, to perform this 
for TSPO receptor.  
During the test, a crude mitochondrial pellet, as the TSPO source, deriving from kidneys 
of male Wistar rats properly treated and diluted, after determination of its protein 
concentration, was incubated with 0.6 nM [3H]PK11195 (well known and studied TSPO 
specific ligand) in ice-cold buffer B (50 mM Tris-HCl, pH 7.4). Then, a range of 
concentration (from 0.1 nM to 10 μM), of every single compound from 8F to 12F was 
added, in a total volume of 0.5 mL. The overall time of incubation was 90 min at a 
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temperature of 4 °C. When finished, the incubation was stopped by dilution with ice-
cold buffer B and then the suspension was filtered and the amount of radioactivity 
retained on the filters was determined. It is really important that all this procedure is 
carried out quickly and at low temperature, not to influence the dissociation rate of the 
complex. Then we derived the IC50 for every compound and subsequently obtained the 
Ki values, according to the commonly used equation of Cheng and Prusoff.  
To quantify the non specific binding activity, the incubation was performed both in the 
presence and in the absence of unlabeled 1 μM PK11195; the concentration of the 
unlabeled ligand has to be higher than that of the receptor, that we had determined first 
with the protein assay, to clearly evaluate the rate of radioligand bound to tissues or 
other structures.  
The results for our compounds, expressed as Ki values derived from the [3H]PK11195 
displacement plots, are illustrated below (Figure 3.5). It is worth mentioning that the 
displacement plot of compound 9 isn’t shown as this molecule had serious solubility 
problems in DMSO, solvent commonly used for the test in standard practice, and it was 
not possible to perform the test. Similarly, compound 9F was only partially soluble in 
DMSO, but in this case we decided to evenly perform the test. Anyway, the results of 
binding could not be accepted because the [3H]PK11195 displacement curve didn’t 
show a regular pattern, failing to reach the x-axis, that is the complete [3H]PK11195 
displacement. For compound 8F, tested before of the other, the binding plot is not 
shown below, but the Ki value derived form [3H]PK11195 displacement was of 0.3 ± 
0.02 nM. 
It should be noted that, during these tests, sometimes we referred to the compounds with 
a different nomenclature than that used up to now, that is the P series. Here, both of 
them are reported, to better understand the following plot:!
- P3 stays for 10F; 
- P4 stays for 9F; 
- P5 stays for 12F; 
- P6 stays for 11F.!
 !
!
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Figure 3.5 [3H]PK11195 displacement curve derived from the TSPO binding of compound 10F 
(P3), 9F (P4), 11F (P5) and 12F (P6). As already mentioned, the P4 plot shows an irregular 
trend, probably due to the poor solubility of 9F in DMSO, which results in a not derivability of 
its Ki real value. !
!
Thanks to a long-standing partnership of my group with Prof. Michael Kassiou, of the 
Brain and Mind Research Institute of Sydney, Australia, it was possible to test for the 
binding assay a wide range of molecules, whose synthesis was performed by Prof. 
Kassiou’s staff. This series, named sb, consists essentially of analogues of DPA-714 
(N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-
yl)acetamide), and it is comparable with our product, since the main difference is the 
ether vs ester functionalization. The synthetic strategy isn’t shown in details, as this 
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work is actually under publication. We performed with the same protocol already 
reported the binding assays for these compounds: their structures together with the 
respective Ki values are reported in the following table (Figure 3.6).  
For both these analogues and our compounds, the selectivity for TSPO of their founders 
(PBR 136, DPA-713 and DPA-714) was previously verified by binding tests towards 
CBR, using [3H]Ro15-1788 displacement in rat brain tissue. !
 
Figure 3.6 Table of sb series substituents, with Ki value of each compounds. On the 
right, the general structure is reported.!
!
Once assessed the affinity and selectivity of all the compounds, since our goal was to 
select molecules potentially valid as therapeutic agents, we had to investigate wether 
they were also able to generate some biological response, in other words to determine 
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their pharmacological profile. So, as TSPO is primarily involved in the synthesis of 
steroids, we planned to carry out the steroidogenesis assay, which is widely accepted to 
predict the profile of a molecule interacting with this receptor. The first results of the 
pregnenolone assay for the analogues of our series and the sb seemed to be encouraging 
in terms of finding new TSPO agonists, but needed to be rearranged a second time, as 
expected by standard practice before being displayed as statistically relevant. As an 
instance, in the following graphic (Figure 3.7) we reported the percentage result in 
pregnenolone increase of compound sb 4025 which, together with sb 3015, can be 
considered a direct analogue of our lead compound PBR 136 (also referred to as 8 
compound). At this regard, it is worth to note that this value is similar for both sb 4025 
and PBR 136, near 24-25% more than that showed by controls (cells incubated with 
only EtOH and DMSO).!
!
!
Figure 3.7 Histogram reporting the preliminary data of percentage increase in pregnenolone 
production of C6 cells after incubation with sb 4025. On the right, comparison between sb 4025 
and PBR 136 structures. !
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At the same time, in agreement with the Australian group, we performed the 
steroidogenesis assay on another set of compounds, previously tested for their binding 
affinity, referred to as Raj, still addressing TSPO receptor but belonging to the family of 
indole-2-carboxamide compounds. The products that gave back the best results in terms 
of affinity, were chosen to carry out the steroidogenesis assay, on rat glioma C6 cells. 
The cells were incubated with the simple salt medium, consisting of 140 mM NaCl, 5 
mM KCl, 1.8 mM CaCl2, 1 mM MgSO4, 10 mM glucose, 10 mM HEPES/NaOH, pH 
7.4, plus 0.1% BSA, with an addition of 25 μM Trilostane and 10 μM SU10603, 
specific inhibitors of 3β-hydroxysteroid dehydrogenase and 17α-hydroxylase, 
respectively, in order to block the further metabolism of pregnenolone. Then, 40 μM 
solutions of the new synthetic compounds and PK11195, as reference compound, were 
added, one at a time, to the 96 multiwell plate, and leaved for two hours. At the end of 
the incubation, the quantity of pregnenolone released by cells in the medium was 
quantified by an immunoenzimatic assay. Briefly, we poured a solution of pregnenolone 
conjugated with the HRP (horseradish peroxidase) enzyme into the wells, and then 
added the HRP substrate TMB (3,3’,5,5’-tetramethylbenzidine); the colorimetric 
reactions developed were evaluated by measuring the absorbance at 450 nm. This is an 
indirect measurement, based on the evidence that the more pregnenolone cells are 
stimulated to produce, the less pregnenolone-HRP will be able to bind.  
We screened compounds Raj 210, 211, 292, 297, 299, 300, 301 and 304, whose general 
or particular structure is reported below, together with the Ki values of some of them 
(Figure 3.8, 3.9, 3.10); the reference compound was still PK11195, but we took in 
account also the effect of EtOH and DMSO, solvents used during the assay. The test 
was performed in triplicate for each compound and the whole procedure was repeated 
two times. Results are shown in the following panel; the percentage of increasing in 
pregnenolone synthesis are high for some compounds, with respect to the EtOH and 
DMSO wells value while, referring to the PK11195 value, the buildup is about 20% 
maximum. As an instance, if we compare the Ki values in rats of PK11195 (3.0 nM) and 
Raj 300 (0.017 nM), a difference in pregnenolone increase of only 20% confirms what 
already known, namely that there is no forced correlation between these two parameters. !
"38
Results
!
!
!
!
!
!
Figure 3.8 General structure of Raj series compounds; the grid on the right shows the Ki value 
of 5 of the 8 molecules subsequently tested with the pregnenolone assay. !
!
!
!
!
!
!
!
!
!
!
Figure 3.9 The above histogram reports the percentage increase in pregnenolone production of 
C6 cells after incubation with Raj compounds 210, 304, 211, 299, 297, 301, 292, 300, with 
PK11195 as reference compound. In the grid is shown the % difference in pregnenolone 
production of the non incubated (EtOH/DMSO) vs the incubated cells and, in the far right 
column, are reported the Dunnett’s multiple comparison test value. !
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Figure 3.10 Structures of five of the eight compounds of Raj series tested with the pregnenolone 
assay, which results are shown above.!
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The availability of all these different chemical structures (PBR, sb and Raj) suggested 
us the idea to perform a SAR study among them. Although, as known, the structure of 
TSPO isn’t already resolved, one of the most commonly accepted TSPO pharmacophore 
model can be represented with the presence of three regions: a freely rotating aromatic 
ring region (FRA), an electron rich zone (δ1), a planar aromatic region (PAR) and a 
lipophilic area (LA). We planned a future investigation of the interactions of these three 
class of compounds with the active site of the receptor, choosing the most active ligands 
for each of the three series to derive a pharmacophore, to be subsequently applied to the 
21 molecules of the whole dataset. The in silica simulation should be carried out with 
the Molecular Discovery FLAP, a software that provides a common reference 
framework for comparing molecules, using molecular interaction fields. 
!
3.4 The imaging target  
 
The second main purpose of my PhD project was addressed to the interest, recently 
sprouted in the last decade, about the potential diagnostic applications of TSPO ligands. 
It goes without saying that the after all recent interest in this direction came with the 
expansion of the imaging techniques (as NMR, PET, SPECT), that highlighted the 
necessity of new selective and potent tracers to be availed.  
As previously described, my research group had already worked at the synthesis of 
tracers deriving from DPA-713 and DPA-714, respectively labeled with 11C and 18F, 
successfully tested as PET tracers and actually used even in NMR and SPECT analysis. 
This time we decided to experiment something different, not labeling directly the 
molecule but using the specific TSPO ligand as a carrier of a radionuclide inserted 
inside a special cage.  
The chosen ligand was PBR 127 (Ki  = 6.3 nM), so we synthesized it as previously 
explained in this section. Then, to join the ligand with the chosen basket to hold the 
proper radionuclide, we decided to insert a pegylated linker. In a previously reported 
paper by Cerutti et al. (2013)114 a similar conjugate was done using an alkyl spacer of 6 
C atoms. So at the beginning we decided to maintain a similar distance between the 
ligand and the radionuclide and that was the reason why the choice was addressed on an 
heterobifunctional H2N-PEG3-OH. The nature of the terminal groups was determined by 
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the will of join the linker to the TSPO ligand with a stable ether bound and the cage to 
the linker with a classic amide bound. Concerning the cage, we decided at first to use a 
DOTA chelator (commercially available as DOTA-tris(tBu)ester, 2-(4,7,10-tris(2-(tert-
butoxy)-2-oxoehtyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid), without prejudice 
to the possibility of subsequently choose between a range of specific chelating agents, 
tailored to the complexation properties of each radiometal and non-radiometal (the 
structure of the conjugate is shown in Figure 3.11). !
The H2N-PEG3-OH was treated 
first to protect the amine group, 
leaving it react overnight with 
Boc2O (di-tert-butyl dicarbonate) 
in CH2Cl2 with DIPEA (N,N-
diisopropylethylamine). The 
reaction was monitored with 
TLC and diluted fluorescamine, 
to verify the presence or not of 
the free amine group.  
                                                          Figure 3.11 DOTA-PEG3-PBR 127 conjugate structure.  
 
 
After that, the hydroxy group was functionalized with tosyl chloride, in dry CH2Cl2 with 
TEA (triethylamine) and then, once this reaction was completed, the intermediate was 
left to react overnight with PBR 127 at 85 °C in DMF with K2CO3. The day after, 
demineralized H2O was poured into the flask and the volume was extracted with EtOAc; 
then, the organic layer was collected and dried under vacuum, to obtain compound c. 
The following passage, deprotection of the amine, was a quick step (45 min) performed 
with 30% TFA (trifluoroacetic acid) in CH2Cl2 and the presence of free amine during the 
reaction was still detected in TLC by fluorescamine.  
Once achieved the d compound, this had to react with DOTA-tris(tBu)ester in DMF, at 
r o o m t e m p e r a t u r e , i n t h e p r e s e n c e o f b o t h H AT U ( 1 -
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate) and NMM (N-methylmorpholine), necessary to form the active 
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ester of the carboxylic acid to force the reaction towards the formation of its products. 
The reaction was monitored by TLC and the solution of p-anisaldehyde as stain color 
for developing TLC plates. The last step, to obtain compound f, was the deprotection of 
the three tBu ester of DOTA carboxyl groups. At first, we proceeded as for the 
deprotection of the compound c; then, after 60 min, we evaporated all the volume in the 
flask, poured inside fresh TFA and left the solution stirring, monitoring every hour the 
progress of the reaction. When finished, compound f was obtained as a yellow solid, 
analyzed by means of NMR and UPLC/ESI-MS and subsequently purified by HPLC/
ESI-MS system, Waters Symmetry 200 Å C18 reverse-phase column (in Figure 3.12 is 
reported in scheme the followed synthetic strategy; Figure 3.13: HPLC/ESI-MS of the 
DOTA-PEG3-PBR 127 conjugate).  
 
         !
                !
!
!
!
              !
Figure 3.12 General synthetic pathway for the attainment of DOTA-PEGn-PBR 127 conjugate.!
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Figure 3.13 HPLC/ESI-MS of DOTA-PEG3-PBR 127 conjugate; tR = 4.77 min. (selected 
gradient 40700506, solvent A (H2O milliQ and 0.1% of TFA), solvent B (CH3CN 84% and 0.1% 
of TFA)); m/z 977 M+; 978 [M + 1], 489 [(M + 2H)/2]+. !
The same procedure already described was used to synthesize another conjugate, that 
differs from the previous one only for the length of the spacer. In fact, in this case we 
used a PEG still functionalized with a free amine end on one side and an hydroxy group 
on the other, but with a molecular weight of 3000. Because of the weight of this PEG, 
the work up of several reactions were more difficult as the compound tended to 
precipitate together with reactions impurities, forming some kind of skeins not easy to 
purify. The reason why we chose to synthesize this second conjugate was the chance to 
benefit of the presence of a PEG long enough to confer all the features that usually have 
the pegylated drugs, as the prolonged permanency in the biological system, the stealth 
effect and the ability to enhance the action of the radionuclide within the molecule, as 
for therapeutic purpose.  
!
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3.5 To bind or not to bind?!
An especially critical point of this project was the prospect that the presence of a spacer 
and a cage, joint in the conjugate to the chosen TSPO ligand, could too much adversely 
affect its ability to bind the receptor. In fact this sort of tail, whatever its length, adds 
weight to the molecule, necessarily varying its tridimensional arrangement. That could 
seriously invalidate the ligand affinity towards TSPO, preventing the functional PBR 
127 spatial conformation needed for the correct receptor interaction.  
In this respect, we chose the PEG3 conjugate to be tested for its ability to compete 
against [3H]PK11195  for the affinity toward TSPO. The test was performed in Pisa, as 
above described for the other compounds, with a range of concentration of the analyzed 
molecule, on mitochondrial pellet deriving from male rats kidneys.  
The results, reported in the image below as [3H]PK11195 displacement curve (Figure 
3.14), showed a binding affinity of the compound, expressed with a Ki value of 0.856 
μM, still very significant, although to a lesser extent compared to that of the free ligand 
PBR 127 (Ki value of 6.3 nM).!
!
Figure 3.14 [3H]PK11195 displacement curve derived from the TSPO binding of DOTA-PEG3 -
PBR127 conjugate.!
!
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3.6 Deep in the labeling matter 
 
3.6.1 111In!
Once assumed the favorable binding profile of the final compound, we chose to examine 
in depth the same conjugate with the labeling trials; regarding the latter perspective, we 
started a collaboration with the équipe of Prof. Alberto Pupi, section director of Nuclear 
Medicine at the AOU of Careggi, Florence. In particular, Doc. A. D’agata and Doc. S. 
Raspanti offered us the chance to perform together several labeling trials, with the 
benefit of their deep experience in this subject.  
As labeling reagent, we decided to work at a first time with 111In chloride, which is one 
of the key radionuclides in preliminary test, since it is readily available, not too much 
expensive and safe to handle.  
For the first trial, a solution 2mg/ml of compound f in CH3CN/H2O 10:90, previously 
aliquoted, was diluted with the ammonium acetate buffer 0.2 M, pH 4-5, to obtain a 
solution 1mg/ml. Then, 10 μl of this solution were taken and added to 100 μl of the 
same ammonium acetate buffer 0.2 M, 90 μl of gentisic acid (10 mg/900 μl), commonly 
used as scavenger, and 100 μl of 111In chloride, to a final volume of the solution of 200 
μl. This mixture was incubated at 90 °C for 20 min. At the end of the reaction, the 
analysis of the quality control assessed the pH value, the TLC-determined 
radiochemical purity and the HPLC-determined radiochemical purity. Then, the mixture 
was purified on a C18 Sep-Pak column, to remove impurities such as unbounded 111In, 
and on the eluted fraction (with an activity equal to a yield of labeling of about 21%) 
containing the 111In-f was newly performed TLC and HPLC determination of 
radiochemical purity. The peak of 111In-f was the most represented, with a total yield of 
57.68% (see Figure 3.15). !
!
!
!
!
!
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Figure 3.15 Radiochemical purity of the labeled conjugate evaluated by TLC and HPLC 
(respectively displayed on the upper and lower graph). The predominant peak in both cases is 
ascribed at the 111In-f complex.!
 
Following the same protocol, several trials were performed (reported in details in the 
Experimental section), varying the volumes of the reagent and, most of all, time and 
temperature of reaction. The best results, in term of percentage yield of radiochemical 
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purity of the final product after purification, were achieved with an incubation at 60 °C 
for 30 min, in the absence of gentisic acid, that gave back a value of 76% (see TLC and 
HPLC chromatogram in Figure 3.16). Although most of the literature concerning DOTA 
radiochemistry relates of higher percentage values of labeling, our best value of 76% 
has really to be considered promising for performing animal trials, and especially 
considering that this yield was principally affected by the non extremely high purity of 
the cold f used in the reactions (75-80%).!
!
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Figure 3.16 Radiochemical purity of the labeled conjugate after reaction carried out at 60 °C 
for 30 min, evaluated by TLC and HPLC.!
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3.6.2 68Ga!
After the significant labeling results obtained with 111In, we thought about the possibility 
to try other radionuclides, such as 68Ga and 177Lu, that display a similar reactivity and 
radiochemistry. 68Ga and 177Lu are, with 111In, two of the most used metals routinely 
used as 90Y surrogates in the labeling of diagnostic and therapeutic agents117. As a plus, 
68Ga has the advantage of being available in cyclotron independent way, via the 68Ge/
68Ga generator system.  
With respect to 68Ga, a variety of radiopharmaceuticals were developed for the imaging 
of different organ functions, even if only few of them had successfully reached the 
clinical use. Though the imaging in clinical practice relies particularly on compounds 
labeled with cyclotron produced 18F and 11C, 68Ga has gained more importance, 
especially for peptide and non peptide probes developed with high tumor affinity (for 
instance, 68Ga-DOTA-TOC118 and 68Ga-DOTA-hEGF119, tracers for the visualization of 
neuroendocrine tumors and the EGFR over expression in tumors, respectively).  
Considered this, we went to IEO (European Institute of Oncology, Milan), thanks to the 
helpfulness of Doc. Stefano Papi, to perform one preliminary 68Ga labeling test in the 
Radiopharmacy laboratories.  
As a first attempt, we decided to use the same protocol of the 68GA-DOTA-TOC, as it 
represents one of the most well known and characterized labeling procedure, and 
because the macrocycle of the two molecules was the same.  
At the moment of our test, the 68Ge/68Ga generator system was able to release an 
activity of 35/37 mCi, which is about 12 pM of pure 68Ga, hence we chose to dilute 10 
μl of the 2mg/ml solution of compound f in 30 μl of H2O (water for injection) to obtain 
the best concentration values for the labeling trial. Then, we took 40 μl of this solution, 
which is 20 μg of cold f, and put it together with 200 μl of sodium acetate buffer 1 M 
and 1 ml of physiological saline in the reaction vessel of the synthesis module CEB 2R 
HE, Radiopharma. As the synthesis started, the generator was eluted with diluted HCl, 
to remove the 68Ga within, and this flow was directed into the reaction vessel, heated to 
95 °C. When all the 68Ga was collected, the solution was heated up to 100 °C for 8 min. 
Then the mixture was pumped through a C18 Sep-Pak column, and physiologic saline 
was poured to remove the unbounded 68Ga (and this flow-through was collected into the 
waste). After the physiologic saline, 50% EtOH in H2O was fluxed through the C18 
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Sep-Pak to elute the 68Ga-f produced, and other side products within, to the final 
collecting flask. In Figure 3.17 below are shown the report modular-lab synthesis plots 
with the trends of activity, respectively measured in the reaction vessel and in the C18 
Sep-Pak column, during the whole reaction time.  
 
Figure 3.17 Trends of activity measured in the reaction vessel (A) and in the C18 Sep-Pak 
column (B), to monitor in progress the reaction. The end of activity in the reaction vessel 
matches the beginning of activity in the column, as these steps are one after another.!
 
During the synthesis, to better estimate the percentage proportion between free and 
labeled 68Ga, we paused for a moment the instrument before the purification step and 
collected 0.5 ml of the crude solution that came out from the reaction vessel. The pH 
measurement on this fraction was near 4.5, which is needed.  
The activity measured at the end of the reaction was of about 5 mCi in 1.5 ml of the 
purified solution, and about 3.4 mCi in 0.5 ml of the crude solution sample. Both the 
sample were analyzed by means of HPLC-UV coupled to a flow scintillation analyzer, 
Radiomatic 150RT PerkinElmer (see Figure 3.18).!
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Figure 3.18 Chromatogram deriving from Radiomatic 150RT (radioactivity transformed in 
mV). In the crude sample (A), the main peak at 3.43 min is ascribable to free 68Ga; in the 
purified sample (B), the main peak at 12.87 min is due to 68Ga-f.!
!
After this first 68Ga labeling trial, we reached a final yield of 68Ga-f of about 30%, 
referring to the total activity released by the generator. In the purified sample, the 
activity due to our labeled compound represented the 56% of the total activity, while the 
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remaining activity was split between a minimal residue of free 68Ga and at least two non 
characterized side products.  
It’s clear that the 68Ga labeling of our compound have to be optimized, evaluating the 
best conditions to improve the percentage of final yield. Anyway, considering that the 
labeling of DOTA-TOC, whose purity as cold precursor is near 98%, gives back a yield 
of about 75%, our 30% of labeling yield obtained with a cold precursor at 75-80% of 
purity, without the aid of a tailored protocol, has to be considered very promising, and 
seems a good encouragement to proceed in these studies. !
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4. DISCUSSION!!
The stimulation of steroids and neurosteroids biosynthesis as the keystone in the process 
of axonal and neuronal regeneration has been extensively studied since the past years, in 
order to derive the causes of the onset and possible treatment of a large number of 
neurological diseases. It’s already clear that the faster way for triggering this process is 
mediated by TSPO, whereby molecules targeting this receptor are deeply investigated 
for their possible neuroprotective action. At the same time, the direct association 
between TSPO concentration levels and the staging of various diseases, as several type 
of cancers, confirms the convenience of having available new powerful ligands, 
endowed with high affinity towards this receptor, as diagnostic tracers for modern 
imaging techniques.  
The outcomes of this research project are aligned with these two topics.  
On the therapeutic approach side, we have focused our interest on the study of new 
synthetic ligands, endowed of particular high affinity towards TSPO, and their ability in 
stimulating the endogenous production of steroid precursor pregnenolone (as proved in 
C6 rat glioma cells). We directly synthesized a small series of compounds, belonging to 
the class of N,N-diethyl-(2-aryl)pyrazolo[1,5-a]pyrimidin-3-ylacetamides, referred to 
also as P series, and then we evaluated their biological activity, together with that of two 
more classes of compounds, sb and Raj, respectively related to the chemical family of 
analogues of DPA-714 and indole-2-carboxamides.  
With regard to the synthesis of the precursors of P products, we followed the classic 
synthetic pathway already reported by our group, while implementing certain critical 
steps by the use of microwave, most of all to remarkably reduce the reaction time and, 
in some cases, with a reasonable increase in terms of yield.  
The first biological evaluation of series P, sb and Raj was to test their specific binding 
abilities. Concerning this aspect, we obtained a set of extremely interesting Ki values, 
many of which in the low micro, low nano and even high pico molar range, some of the 
lowest values currently available between the synthetic ligands currently studied or in 
trials.  
Although SAR studies are still under development, in addition to the already clarified 
importance of presence and length of the amide chain at position 3 of the 
pyrazolopyrimidine scaffold and the key role of the substitutions on the pyrimidine 
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moiety in directing the selectivity towards TSPO (instead of CBR), it seems reasonable 
to assume that groups providing steric hindrance, bound at para- position of the 2-
phenyl ring, promote a gain in affinity. As preliminary observation, we had the best 
affinity results with aromatic and cycloalkyl groups, compared to alkyl chains.  
Despite the excellent affinity values found for most of the new synthetic ligands of the 
three series, only a part of them has shown likewise favorable pharmacological profile 
as TSPO agonist. Such a result didn’t come unexpected, since, as highlighted by several 
studies, it is still not possible to ascertain a correlation between affinity and intrinsic 
activity of TSPO ligands (here measured as steroidogenic activity), despite the large 
number of structures synthesized and investigated to date. In general we can say that 
several of the tested molecules displayed functional effects which did not correlate to 
the binding trend observed in competition assay. These evidences further complicate the 
development of TSPO agonists for therapeutic purposes. In summary, some of the tested 
molecules showed a significant efficiency in inducing the cellular production of 
pregnenolone, in some cases with an increase of even more than 80% compared to 
controls. On the other side, several compounds that showed very promising Ki values, 
didn’t significantly affect the steroids production or revealed pregnenolone percentage 
values even lower than that shown by controls.  
Anyway, the molecules found to be the most efficient in significantly increasing the 
endogenous pregnenolone percentage in rat cells will be subsequently tested on human 
astrocytes and SH-SY5Y neuroblastoma cells for their ability in generating protective 
effects against neuroinflammation and neurodegeneration human models, as a further 
and more reliable evidence of their potential development for therapeutic use.  
 
Concerning the diagnostic approach, as formerly reported, my research group had 
investigated (in a previous study of 2008)111 the labeling and in vivo evaluation in 
rodents and baboons by micro-PET and PET imaging of TSPO ligands [11C]DPA-713 
and [18F]DPA-714, in collaboration with Prof. M. Kassiou’s research group in Sidney. 
This time we decided to synthesize a new TSPO targeting conjugate, with an articulated 
structure composed of a TSPO ligand (PBR 127), a spacer and a DOTA cage (explained 
in details before) to be chosen as imaging tracers, but with the possibility to make it 
usable even as therapeutic radiopharmaceutical. The project provided for the synthesis 
of two conjugates, which diversified themselves for the length of the pegylated spacer, 
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so the followed synthetic strategy was the same in both cases, even if we had to adapt 
the work up of some reactions because the longer PEG gave problems of precipitation 
of the compound and complicate the purification steps. Given these problems, once 
attained the final conjugates we decided to use the one with the shorter PEG chain to 
perform binding test, as an initial evaluation parameter of its possible maintenance of 
affinity towards TSPO. The results were encouraging, with an obtained Ki value of 
0.856 μM which, although less good than that of the free ligand PBR 127 (Ki of 6.3 
nM), still remains significant and undoubtedly gives way to the idea of attempting the in 
vivo tests.  
After this preliminary biological evaluation, we chose to perform the first labeling of the 
same conjugate f with 111In radionuclide at the AOU of Careggi, Florence. In this 
respect, we carried out seven labeling tests, at first following the general instructions 
given by literature and in a second moment varying different parameters of reagents, 
time and temperature, with the aim to optimize the obtainment of the radiolabeled 
compound. Although the most common conditions for the charging of DOTA cage 
report high temperature values (usually near 90 °C) and longer reaction time, we found 
the best results, in terms of TLC and HPLC measured radiochemical purity of the final 
compound, in performing the reaction at 60 °C for 30 min, reaching a 75.9% yield. This 
percentage of radiochemical purity is already quite acceptable for preliminary in vivo 
tests, however can be further improved increasing the purity of the unlabeled conjugate 
as, for these preliminary tests, we used a 75-80% pure compound.  
Concerning the 68Ga labeling, even though we can rely only on one test, the same 
evaluations made for 111In about the purity of the cold compound can be considered 
crucial for improving the final labeling yield. As the DOTA macrocycle is the same for 
the two molecules, we performed the labeling of compound f using the 68Ga-DOTA-
TOC protocol, which was optimized years ago and is by now well known and 
commonly applied. Anyway, both with the already mentioned limitations due to the 
purity of the cold compound, there may be different parameters to be set during the 
synthesis, more suitable for the best labeling conditions of our conjugate. Still, the final 
68Ga-f yield of 30% and its 56% radiochemical purity, was a remarkable result, 
consistent with what expected for the first attempt. 
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5. CONCLUSIONS!
The interest in TSPO ligands as potential therapeutic agents or efficient tracers for 
imaging techniques stayed strong during these years. In particular, referring to 
molecules belonging to the pyrazolo[1,5-a]pyrimidines class, several studies have 
investigated DPA-714 and its fluorinated analogue, [18F]DPA-714; the latter has recently 
attained the clinical trials. As an instance, it is currently in progress, at the University 
Hospital of Tours, a pilot study of [18F]DPA-714 as biomarker of neuroinflammation in 
cognitive decline on healthy patients and two groups of volunteers affected by mild to 
moderate Alzheimer’s disease and amnestic mild cognitive impairments (see references 
at clinicaltrials.gov). Such investigations seem even more desirable considering that, at 
the state of the art, there are no definitive procedures for the determination of the early 
onset of numerous neurodegenerative diseases such as Alzheimer’s and dementia. This 
aspect goes together with the fact that several of these pathologies, at the beginning, 
cause cognitive changes, the so called mild cognitive impairments, that are serious 
enough to be noticed by the individuals experiencing them or to other people but, at the 
same time, not severe enough to interfere with daily life or independent function, further 
delaying the possibility of correct diagnosis and therapeutic approach.  
This work integrates the studies on TSPO ligands introducing new synthetic compounds 
of the same family of DPA-714 and their preliminary biological evaluation, together 
with that of two more classes of molecules, the chemically related sb series, and the Raj 
series. Some of the compounds showed both high affinity towards the receptor and 
promising pregnenolone induction in rat cells, with respect to controls and to the 
reference compound PK11195, leaving the door open for further investigations to be 
performed on human astrocytes and SH-SY5Y neuroblastoma cells, as already 
mentioned, to additionally test their potential as anti-inflammatory and neuroprotective 
agents.  
Concerning the second line of this project, namely the design of a conjugate to be 
studied as a diagnostic/therapeutic agent (in summary, a theranostic tool), we 
synthesized two compounds, differentiated only by the spacer length. The compound 
with the shorter PEG chain showed good affinity results, when tested for its binding 
ability, and even the labeling trials with 111In gave back promising results.  
The next labeling step with 68Ga, that gave back a remarkable preliminary result, was 
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performed thinking about the possibility to successively replace this radionuclide with 
90Y, as potential therapeutic agent. In fact, the 68Ga and 90Y radiochemical behavior is 
quite the same, but 68Ga is much more simple and safe to handle during the trials.  
Obviously, the possibility to perform in vivo tests (analyzed, for instance, by the micro-
PET/SPECT/CT instrument in Careggi) will be the further needful stage to evaluate 
crucial parameters as the biodistribution and bioavailability.  
As for the compound with the longer PEG chain, we would have thought very 
preliminary, depending on the results of binding test, to a possible use as diagnostic/
therapeutic agent, to be carried by the lymphatic system for the identification of 
metastatic cells, directly correlated with cancer staging and malignancy. Another 
hypothesis could be to exploit the ability, given by the longer PEG, to have an extended 
permanence in the body, together with the low immunogenicity, and the deriving 
benefits for therapeutic purposes.  
To end, seems really significant to point out how crucial is today the need to have 
available specific PET tracers especially for the recognition of Alzheimer’s disease, 
whose approved diagnosis is currently entrusted only to a post mortem examination. 
The research, in this topic, has focused particularly on the evaluation of neuritic 
plaques, but this choice is showing many limitations. As an instance, in 2011 the FDA 
approved a new PET scanning radiopharmaceutical compound, Amyvid™ (18F-
Florbetapir injection), acquired by Eli Lilly and Company. This radiotracer is indicated 
for brain imaging with PET for the assessment of the neuritic plaque beta amyloid 
density in patients with cognitive disfunction, under evaluation for Alzheimer’s disease. 
In particular, a negative Amyvid™ scan indicates sparse or absence of neuritic plaques 
and is inconsistent with a neuropathological diagnosis of Alzheimer’s disease when 
performing the analysis. Anyway, even if a positive scan indicates the presence of 
moderate to frequent amyloid beta plaques, it is not credited for the Alzheimer’s disease 
diagnosis and cannot discriminate between this disease and others cognitive disorders. 
In addition, the safety and efficacy of Amyvid™ have not been tested neither for the 
prediction of development of other neurological diseases, such as dementias, nor for the 
monitoring of the responses to therapies. In this context, the choice to target the TSPO 
receptor, which is known to be a highly sensitive biomarker of even slight alterations of 
neuronal physiological state, seems the most promising for a future perspective of early 
and safe diagnosis of several widespread neurological diseases.
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6. EXPERIMENTAL!
6.1 Data analysis  
 
6.1.1 Chemical data!
1H-NMR spectra for characterization of synthesized products have been recorded on a 
Bruker Avance (400 MHz) apparatus or on a Varian Gemini (200 MHz) apparatus using 
the hydrogenated residue of the deuterated solvents CDCl3(d = 7.26 ppm) or 
CD3COCD3 (d=3.31 ppm) for 1H-NMR. Chemical shifts are reported in ppm (parts per 
million) downfield from TMS. Multiplicities are reported as s (singlet), d (doublet), t 
(triplet), q (quadruplet), m (multiplet) and b (broad).  
Melting points have been determined with a Gallenkamp apparatus and were 
uncorrected.  
The purity of samples was assessed by means of TLC, performed on Merck silica gel 
plates F 254. Silica gel (Merck Grade 9385, 230-400 mesh) was used for flash 
chromatography column.  
UPLC/ESI-MS analysis have been performed on a Waters Symmetry 300 Å C18 
reverse-phase column (100 mm x 2.1 mm, ID 3.5 μ), 0.60 ml/min flux. MS grade 
CH3CN and TFA were purchased from Sigma-Aldrich. The selected gradient was 
50700506, with solvent A (H2O milliQ and 0.1% of TFA) and solvent B (CH3CN 84% 
and 0.1% of TFA); injected volume: 10 μl.  
Purification was performed by means of HPLC/ESI-MS system, Waters Symmetry 200 
Å C18 reverse-phase column (250 mm x 4.6 mm, ID 5 μ), 1 ml/min flux. The selected 
gradient was 407030, with solvent A(H2O milliQ and 0.1% of TFA) and solvent B 
(CH3CN 84% and 0.1% of TFA)."
6.1.2 Biological data!
The pregnenolone assay was performed by means of IBL Pregnenolone ELISA 96 Best/
determ. kit.  
Absorbance values have been recorded at 450 nm on a Perkin Elmer Victor2 Wallac, 
1420 Multilabel Counter. 
!
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6.1.3 Radiochemical data!
- 111In.  
111In chloride Mallinckrodt, solution 370 MBq/ml (time of arrival). For compound 
labeling 100 μl were collected (0.0215 nM), with an activity at the time of calibration of 
37 MBq, 1mCi.  
Ratio compound:111In = 10.2/0.0215 = 476:1.  
Ammonium acetate buffer 0.2 M, pH 4-5:  
- 3.0833 g of ammonium acetate (Baker cat. 0390, MW 77.0825) were made up to the 
volume of 200 ml with milli q water;  
-1.59 ml of ammonium hydroxide 30-33% (Sigma Aldrich cat. 05002, MA 35.05, d = 
0.88) were made up to a volume of 200 ml with milli q water, to a 2 M solution;  
- 2.29 ml of glacial acetic acid (Carlo erba cat. 401392, MW 60.05, d = 1.049) were 
made up to a volume of 200 ml with milli q water to a 0.2 M solution.  
Sodium acetate buffer 0.1 M, pH 5.5:  
- 820.35 mg of anhydrous sodium acetate (Carlo Erba cat. 478166, MW 82.035) were 
dissolved in 100 ml milli q water to obtain a solution 0.1 M;  
- 0.572 ml of acetic acid (Merck cat. 1.00063) were made up to a volume of 100 ml with 
milli q water to a 0.1 M solution.  
To obtain a pH value of 5.5, 84.5 ml of alkaline solution were mixed with 15.5 ml of 
acid solution.  
Hepes buffer 0.1 M, pH 5.5: 
- 2.383 g of Hepes (acid, MW 238.3 pKa 7.55 at 20 °C) were made up to a volume of 
100 ml with milli q water;  
- 400 mg of sodium hydroxide (Carlo Erba cat. 480507, MW 40) were made up to a 
volume of 100 ml with milli q water to a solution 0.1 M.  
To obtain a pH value of 5.5, 99 ml of acid solution were mixed with 0.8802 ml of 
alkaline solution.  
Quality control were performed on TLC and HPLC.  
Whatman CHR chromatography paper (eluent: ammonium acetate 10%/CH3OH (1:1)); 
ITLC-SG chromatography paper (eluent: trisodium citrate 0.1 M in HCl 0.2 M).  
HPLC reverse-phase analytic column Alltima C18, 5 μ, 4.6 x 250 mm + pre-column 
Alltima C18, 5 μ, 4.6 x 7.5 mm, Grace Davison Discovery Sciences. Solvent A (H2O 
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milliQ and 0.1% of TFA) and solvent B (CH3CN 84% and 0.1% of TFA). The selected 
gradient was 58020. Injected volume: 20 μl."
- 68Ga. 
We can not report the whole procedure in details, as we performed this test with 
protocols developed at the IEO. We briefly indicate below the principal instrumentation 
and reagents.  
The labeling was performed in the synthesis module CEB 2R HE, Radiopharma, which 
includes a 68Ge/68Ga generator.  
During the synthesis were used sodium acetate buffer 1 M, pH 4.5, physiological saline 
and EtOH 50%.  
Quality control were performed on HPLC-UV and flow scintillation analyzer.  
HPLC reverse-phase analytic column Alltima C18, 5 μ, 4.6 x 200 mm, Grace Davison 
Discovery Sciences. Solvent A (H2O milliQ and 0.1% of TFA) and solvent B (CH3CN 
84% and 0.1% of TFA). The selected gradient was 58020. Injected volume: 10 μl.  
Flow scintillation analyzer, Radiomatic 150RT PerkinElmer. "
6.2 Chemistry of PBR 136 analogues!
3-(4-methoxyphenyl)-3-oxopropanal (1) 
To a solution of NaH (60% dispersion in mineral oil, 83 mM, MW 24.00) in anhydrous 
toluene (70 mL), stirred at room temperature, was added drop wise a solution of 1-(4-
methoxyphenyl)ethanone (83 mM, MW 150.17) and ethyl formate (45 mM, MW 74.08) 
in anhydrous toluene. From the addition on, the flask is placed in ice bath checking the 
temperature, that has to remain under 65 °C. The reaction was carried out for 6 h.  
At the end, the final product was obtained as a light yellow solid (90% yield) and, after 
filtration with diisopropyl ether, dried under vacuum. 1H NMR (CDCl3, 400 MHz) δ: 
3.68 (d, 2H, C=OCH2C=O), 3.85 (s, 3H, OCH3), 7.12 (d, 2H, Ph), 7.85 (d, 2H, Ph), 9.74 
(t, 1H, O=CH)."
5-(4-methoxyphenyl)isoxazole (2)  
A solution of NH2OH hydrochloride (80mM, MW 69.49) in EtOH (40 ml) was stirred at 
room temperature. To promote the solubility, demineralized water was dribbled in the 
flask. After the almost complete solubilization, compound 1 (75 mM, MW 178.18) was 
added and the solution was heated to reflux for 2 h.  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At the end of the reaction, the suspension obtained was filtered and the liquid phase was 
collected and evaporated under vacuum, to achieve the final product as a white, pearly 
solid (85% yield).  
1H NMR (CDCl3, 400 MHz) δ: 3.88 (s, 3H, OCH3), 6.42 (s, 1H, O-C=CH), 7.01 (d, 2H, 
Ph), 7.75 (d, 2H, Ph), 8.27 (s, 1H, CH=N)."
3-(4-methoxyphenyl)-3-oxopropanenitrile (3)  
MeOH (30 ml) was stirred in a flask, at room temperature, and Na metal (2 eq., MW 
22.99) was added gradually until complete dissolution. Then, 2 (1 eq., MW 175.18) was 
added to the solution and the whole was heated to reflux for 5 h. The resulting solution 
was reduced in volume under vacuum, some drops of water were added and a filtration 
occurred, to separate some solids residues. After, concentrated HCl was dropped in the 
solution until complete acidification of pH. At this time was clear the formation of a 
solid bulk of a slightly yellow color. The bulk was dried and crystallized from EtOH.  
The final product was achieved as a needle-shaped solid of clear brown color (80%).  
1H NMR (CDCl3, 400 MHz) δ: 3.68 (s, 2H, CH2-CN), 3.89 (s, 3H, OCH3), 7.06 (d, 2H, 
Ph), 7.78 (d, 2H, Ph)."
3-cyano-N,N-diethyl-4-(4-methoxyphenoyl)-4-oxobutanamide (4) 
To a solution of 3 (5.71 mM, MW 175.18) and 2-chloro-N,N-diethylacetamide (5.71 
mM, MW 149.62, d 1.089 g/ml) in 80% EtOH (40 ml), NaOH (5.71 mM, MW 40.00) 
and KI (17.1 mM, MW 166.00) were added. The mixture was irradiated in an Explorer 
48, CEM microwave system reactor at 80 °C for 40 min. When completed, the mixture 
was filtered and extracted with CH2Cl2. The residue was concentrated and purified with 
flash chromatography on silica gel (Hexane/Ethyl acetate = 50/50, V:V) to afford 4 
(70% yield) as a brown oil.  
1H-NMR (CDCl3, 400 MHz)δ: 1.11 (t, 3H, N(CH2CH3)), 1.29 (t, 3H, N(CH2CH3)), 2.97 
(dd, 1H, CH2), 2.73 (dd, 1H, CH2), 3.40 (q, 2H, N(CH2CH3)), 3.52 (q, 2H, N(CH2CH3)), 
3.91 (s, 3H, OCH3), 5.00 (m, 1H, CH), 7.00 (d, 2H, Ph), 8.05 (d, 2H, Ph)."
2-(3-amino-5-(4-methoxyphenyl)-1H-pyrazol-4-yl)-N,N-diethylacetamide (5)  
To a solution of 4 (3.95 mM, MW 316.35) in EtOH (18 ml) were added to hydrate 
hydrazine (3.95 mM, MW of the anhydrous basis 32.05) and AcOH (0.13 ml, MW 
60.05). The mixture was irradiated at 90 °C for 40 min in the CEM Explorer 48. When 
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completed, the residue was washed with saturated aqueous Na2CO3 (50 ml) and 
extracted with CH2Cl2 (x3). The organic layer was then collected and concentrated 
under vacuum. Purification of the residue by flash chromatography on silica gel 
(CH2Cl2/MeOH = 100/0 - 90/10, V:V) afforded 5 as yellow crystals (42% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 0.86 (t, 3H, N(CH2CH3)), 1.03 (t, 3H, N(CH2CH3)), 
2.99 (q, 2H, N(CH2CH3)), 3.26 (q, 2H, N(CH2CH3)), 3.45 (s, 2H, CH2C=O), 3.77 (s, 
3H, OCH3), 5.71 (s, 2H, NH2), 6.85 (d, 2H, Ph), 7.27 (d, 2H, Ph). "
       "
N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-
yl)acetamide (6)!
To a solution of 5 (1.65 mM, MW 302.37) in EtOH (8.0 ml) was added 2,4-
pentanedione (1.65 mM, MW 100.12, d 0.980 g/ml). The mixture was irradiated with 
Explorer 48 at 160 °C for 30 min. Following the reaction, the residue was purified by 
flash chromatography (CH2Cl2/MeOH = 100/0 - 90/10, V:V) to afford 6 (80% yield) as 
brown crystals.  
1H-NMR (CDCl3, 400 MHz) δ: 1.13 (t, 3H, N(CH2CH3)), 1.22 (t, 3H, N(CH2CH3)), 
2.57 (s, 3H, CH3), 2.76 (s, 3H, CH3), 3.42 (q, 2H, N(CH2CH3)), 3.52 (q, 2H, 
N(CH2CH3)), 3.85 (s, 3H, OCH3), 3.96 (s, 2H, CH2C=O), 6.53 (s, 1H, CH), 6.99 (d, 2H, 
Ph), 7.78 (d, 2H, Ph). "!
N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-bis(trifluoromethyl)pyrazolo[1,5-
a]pyrimidin-3-yl)acetamide (6F)!
Same procedure as above, using DMF (2.5 ml, instead of EtOH), 
hexafluoroacetylacetone instead of 2,4-pentanedione (MW 208.06, d 1.47 g/ml) and 
irradiating at 130 °C and 300 W, for three times in power cycle modality. The solution 
was reduced in volume under vacuum, added of some demineralized water and 
extracted with EtOAc (10 ml x 3). The residue was purified by flash chromatography on 
silica gel (CH2Cl2/MeOH = 100/0 - 90/10, V:V) and the final product afforded as bright 
yellow crystals (70% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.71 (t, 3H, N(CH2CH3)), 1.34 (t, 3H, N(CH2CH3)), 
3.46 (q, 2H, N(CH2CH3)), 3.61 (q, 2H, N(CH2CH3)), 3.89 (s, 3H, OCH3), 4.06 (s, 2H, 
CH2C=O), 7.04 (d, 2H, Ph), 7.39 (s, 1H, CH), 7.89 (d, 2H, Ph)."
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N,N-diethyl-2-(2-(4-hydroxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-
yl)acetamide (7)!
A solution of 6 (1.5 mM, MW 366.46) in aqueous HBr (48%, MW 80.91, d 1.49 g/ml)) 
was heated to reflux and left overnight. When completed, the mixture was washed with 
saturated aqueous NaHCO3 and extracted with EtOAc (10 ml x 3). The final product 
was purified by flash chromatography on silica gel (CH2Cl2/MeOH = 100/0 – 90/10, 
V:V) to afford 7 (65% yield) as white crystals.  
1H-NMR (CDCl3, 400 MHz) δ: 1.13 (t, 3H, N(CH2CH3)), 1.22 (t, 3H, N(CH2CH3)), 
2.57 (s, 3H, CH3), 2.76 (s, 3H, CH3), 3.42 (q, 2H, N(CH2CH3)), 3.52 (q, 2H, 
N(CH2CH3)), 3.85 (s, 3H, OCH3), 3.96 (s, 2H, CH2C=O), 6.53 (s, 1H, CH), 7.03 (d, 2H, 
Ph), 7.82 (d, 2H, Ph).!
N,N-diethyl-2-(2-(4-hydroxyphenyl)-5,7-bis(trifluoromethy)lpyrazolo[1,5-
a]pyrimidin-3-yl)acetamide (7F)!
Same procedure as above, using 6F instead of 6 (MW 474.40). The final product, 
purified with flash chromatography on silica gel (CH2Cl2/MeOH = 100/0 – 90/10, V:V) 
was afford as deep yellow crystals.  
1H-NMR (CDCl3, 400 MHz) δ: 1.71 (t, 3H, N(CH2CH3)), 1.34 (t, 3H, N(CH2CH3)), 
3.46 (q, 2H, N(CH2CH3)), 3.61 (q, 2H, N(CH2CH3)), 3.89 (s, 3H, OCH3), 4.06 (s, 2H, 
CH2C=O), 6.98 (d, 2H, Ph), 7.27 (s, 1H, CH), 7.78 (d, 2H, Ph)."
6.2.1 General procedure for the synthesis of compounds 8-9; 8F-12F!
To a solution of TEA (1.5 eq.) in CH2Cl2 (10 ml) dried on molecular sieves, under N2 
atmosphere, the suitable 2-substituted-pyrazolo[1,5-a]pyrimidin-3-yl)acetamide (1 eq.) 
was added with the proper acid chloride (1.5 eq.). Reaction was stirred over night at 
room temperature. When finished, the suspension was filtered and the filtrate was 
concentrated and purified by flash chromatography on silica gel (Tol/EtOAc = 
100/0-80/20, V:V), to obtain the corresponding ester. "
4-(3-(2-(diethylamino)ethyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl 
benzoate (8)  
This compound was obtained from 7 (0.1 mM, MW 352.43), benzoyl chloride (0.15 
mM, MW 140.57, d 1.21 g/ml) and TEA (0.15 mM, MW 101.19, d 0.728 g/ml) as light 
brown crystals (50% yield).  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1H-NMR (CDCl3, 400 MHz) δ: 1.13 (t, 3H, N(CH2CH3)), 1.24 (t, 3H, N(CH2CH3)), 
2.50 (s, 3H, CH3), 2.73 (s, 3H, CH3), 3.46 (q, 2H, N(CH2CH3)), 3.61 (q, 2H, 
N(CH2CH3)), 3.85 (s, 3H, OCH3), 7.10 (s, 1H, CH), 7.30 (d, 2H, Ph), 7.52 (t, 2H, Bz), 
7.65 (t, 1H, Bz), 7.99 (d, 2H, Ph), 8.13 (d, 2H, Bz)."
4-(3-(2-(diethylamino)-2-oxoehtyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-
yl)phenyl 4-methylbenzenesulfonate (9)  
This compound was obtained from 7 (0.2 mM, MW 352.43), 4-methylbenzenesulfonyl 
chloride (0.25 mM, MW 190.65) and TEA (0.25 mM, MW 101.19, d 0.728 g/ml) as 
bright yellow crystals (40% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.12 (t, 3H, N(CH2CH3)), 1.22 (t, 3H, N(CH2CH3)), 
2.36 (s, 3H, CH3), 2.48 (s, 3H, CH3), 2.70 (s, 3H, CH3), 3.44 (q, 2H, N(CH2CH3)), 3.60 
(q, 2H, N(CH2CH3)), 4.01 (s, 2H, CH2C=O), 7.28 (s, 1H, CH), 7.38 (t, 2H, Ph), 7.43 (d, 
2H, Tol), 8.03 (d, 2H, Ph), 8.26 (d, 2H, Tol).!
4-(3-(2-(diethylamino)ethyl)-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-
yl)phenyl benzoate (8F)  
This compound was obtained from 7F (0.1 mM, MW 460.37), benzoyl chloride (0.15 
mM, MW 140.57, d 1.21 g/ml) and TEA (0.15 mM, MW 101.19, d 0.728 g/ml) as 
yellow crystals (40% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.18 (t, 3H, N(CH2CH3)), 1.37 (t, 3H, N(CH2CH3)), 
3.46 (q, 2H, N(CH2CH3)), 3.60 (q, 2H, N(CH2CH3)), 4.08 (s, 2H, CH2C=O), 7.37 (d, 
2H, Ph), 7.44 (s, 1H, CH), 7.56 (t, 2H, Bz), 7.68 (t, 1H, Bz), 8.01 (d, 2H, Ph), 8.27 (d, 
2H, Bz)."
4-(3-(2-(diethylamino)ethyl)-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-
yl)phenyl 4-methylbenzenesulfonate (9F)  
This compound was obtained from 7F (0.1 mM, MW 460.37), 4-methylbenzenesulfonyl 
chloride (0.15 mM, MW 190.65) and TEA (0.15 mM, MW 101.19, d 0.728 g/ml) as 
deep brown crystals (35% yield).  
1H-NMR (CDCl3 , 200 MHz) δ: 1.09 (t, 3H, N(CH2CH3)), 1.29 (t, 3H, N(CH2CH3)), 
2.46 (s, 3H, CH3), 3.37 (q, 2H, N(CH2CH3)), 3.49 (q, 2H, N(CH2CH3)), 3.99 (s, 2H, 
CH2C=O), 7.11 (d, 2H, Ph), 7.31 (s, 1H, CH), 7.37 (d, 2H, Tol), 7.73 (d, 2H, Ph), 7.86 
(d, 2H, Tol).  "
#64
Experimental
4-(3-(2-(diethylamino)ethyl)-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-
yl)phenyl 4-fluorobenzoate (10F) 
This compound was obtained from 7F (0.1 mM, MW 460.37), 4-fluorobenzoyl chloride 
(0.15 mM, MW 158.56, d 1.342 g/ml) and TEA (0.15 mM, MW 101.19, d 0.728 g/ml) 
as bright yellow crystals (32% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.16 (t, 3H, N(CH2CH3)), 1.47 (t, 3H, N(CH2CH3)), 
3.46 (q, 2H, N(CH2CH3)), 3.60 (q, 2H, N(CH2CH3)), 4.07 (s, 2H, CH2C=O), 7.23 (t, 
2H, FBz), 7.38 (d, 2H, Ph), 7.44 (s, 1H, CH), 8.02 (d, 2H, Ph), 8.27 (dd, 2H, FBz).!
4-(3-(2-(diethylamino)ethyl)-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-
yl)phenyl 2-fluorobenzoate (11F) 
This compound was obtained from 7F (0.3 mM, MW 460.37), 2-fluorobenzoyl chloride 
(0.45 mM, MW 158.56, 1.328 g/ml) and TEA (0.45 mM, MW 101.19, d 0.728 g/ml) as 
bright yellow crystals (30% yield).  
1H-NMR (CDCl3, 200 MHz) δ: 1.18 (t, 3H, N(CH2CH3)), 1.35 (t, 3H, N(CH2CH3)), 
3.46 (q, 2H, N(CH2CH3)), 3.60 (q, 2H, N(CH2CH3)), 4.07 (s, 2H, CH2C=O), 7.28 (s, 
1H, CH), 7.39 (d, 2H, Ph), 7.41 (m, 2H, FBz), 7.56 (m, 1H, FBz), 8.01 (d, 2H, Ph), 8.18 
(m, 1H, FBz).!
4-(3-(2-(diethylamino)ethyl)-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-
yl)phenyl furan-2-carboxylate (12F)  
This compound was obtained from 7F (0.1 mM, MW 460.37), 2-furoyl chloride (0.15 
mM, MW 130.53, d 1.324 g/ml) and TEA (0.15 mM, MW 101.19, d 0.728 g/ml) as light 
brown crystals (32% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.17 (t, 3H, N(CH2CH3), 1.36 (t, 3H, N(CH2CH3)) 3.44 
(q, 4H, N(CH2CH3)), 3.58 (q, 4H, N(CH2CH3)), 4.07 (s, 2H, CH2C=O), 6.64 (m, 1H, 
Fur), 7.28 (s, 1H, CH), 7.36 (d, 2H, Ph), 7.44 (m, 1H, Fur), 7,27 (m, 1H, Fur), 8.00 (d, 
2H, Ph)."
6.3 General procedure for DPA ether analogues (Prof. Michael Kassiou, University 
of Sydney, Australia)!
Commercial methyl 4-hydroxybenzoate (I) was quantitatively protected as its isopropyl 
ether and treated with conjugate base of CH3CN, to obtain cyanoacetophenone (II). 
Subsequently, cyanoacetophenone was deprotonated to the corresponding enolate, 
#65
Experimental
following with treatment with excess of N,N.diethylbromoacetamide, to give crude 
(III). The latter product was condensed with hydrate hydrazine, to yield aminopyrazole 
(IV); a subsequent condensation of IV with 2,4-pentanedione generated the 
pyrazolopyrimidine core (V). Cleavage of the isopropyl ether with aluminum chloride 
afforded common phenolic precursor.  
Starting from V, with a mild heating in the presence of the appropriate alkyl bromide 
and K2CO3 the alkylation of phenolic OH provide the DPA analogues.!
6.4 Membrane preparation and binding assay!
For binding studies, mitochondria were prepared from kidneys of male Wistar rats. 
Kidneys were homogenized in 20 volumes of ice-cold 50 mM Tris/HCl, pH 7.4, 0.32 M 
sucrose, 1 mM EDTA (buffer A), containing protease inhibitors (160 μg/ml 
benzamidine, 200 μg/ml bacitracine and 20 μg/ml soybean trypsin inhibitor) and 
centrifuged for 10 min at 600 g at 4°C. The resulting supernatant was centrifuged for 10 
min at 10,000 g at 4°C. The pellet was then suspended, homogenized in 20 volumes of 
ice-cold 50 mM Tris/HCl, pH 7.4 (buffer B) and centrifuged for 10 min at 10,000 g at 
4°C. The crude mitochondrial pellet was frozen at -20°C until the time of assay or 
incubated with 0.6 nM [3H]PK11195 in buffer B, with a range of concentrations of the 
tested compounds (from 0.1 nM to 10 μM) in a total volume of 0.5 ml for 90 min at 
4°C. 
The incubation was stopped by dilution to 5 ml with ice-cold buffer B, immediately 
followed by rapid filtration through glass fiber Whatman GF/C filters. The filters were 
then washed two times with 5 ml of buffer B and the amount of radioactivity retained on 
the filters was determined by Packard 1600 TR liquid scintillation counter at 66% 
efficiency. Non specific binding was estimated in the presence of unlabeled 1 μM 
PK11195. All experiments were performed in triplicate.  
For the active compounds, the IC50 values were determined and Ki values were derived 
according to the equation of Cheng and Prusoff. Protein concentration was estimated by 
the method of Lowry et al., with bovine serum as standard. "
6.5 Cell culture!
Rat glioma C6 cells were cultured in Dulbecco’s Modified Eagle Medium, 
supplemented with 10% FBS, 1% L-glutamine, 1% Penstrep.  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Cultures were maintained in a humidified atmosphere of CO2/air (5% and 95%, 
respectively) at 37 °C."
6.6 Steroids biosynthesis!
C6 cells were seeded in 96 well plates at a density of ∼1x104 cells/well in a final volume 
of 60 μl. 
The cells were washed three times with a simple salts medium consisting of 140 mM 
NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgSO4, 10 mM glucose, 10 mM HEPES/
NaOH, pH 7.4, plus 0.1% BSA. During experiments, cells were incubated with this 
simple salts medium in CO2/air (5%/95%) incubator at 37°C. In order to measure 
pregnenolone secreted into the medium, its further metabolism was blocked by addition 
of 25 μM Trilostane (2a, 4a, 5a, 17b-4,5epoxy-17-hydroxy-3-oxoandrostane-2-
carbonitrile) and 10 μM SU10603 (1, 2, 3, 4-tetrahydro-4-oxo-7-chloro-2-
naphthylpyridine), inhibitors of 3β-hydroxysteroid dehydrogenase and 17α-
hydroxylase, respectively, to the simple salts medium. Trilostane and SU10603 were 
gifts from Dr. D. Zister (University of Dublin, Dublin, Ireland) and Novartis Farma 
(Varese, Italy), respectively.  
The addition of the novel compounds (Raj 210, 211, 292, 297, 299, 300, 301, 304) and 
of PK11195 to the C6 cells was made by complete change of the simple salts medium to 
the medium containing 40 μM concentration of the different compounds above 
mentioned.  
The secreted pregnenolone in cell medium was measured with an enzyme immunoassay 
(IBL Pregnenolone ELISA kit).  
Briefly, cell salt medium was retained and centrifuged at 1500 g for 10 min and used for 
quantitative determination of pregnenolone. 100 μl/well of the working solution of 
pregnenolone-HRP and 300 (x3) μl/well of wash buffer were prepared. 50 μl of each 
calibrator, control and specimen sample were pipetted into the correspondingly labeled 
wells in duplicate for the first two and in triplicate for the others. 100 μl of the conjugate 
working solution were pipetted into each well and the plate was incubated for 1 h on a 
plate shaker (at approximately 200 rpm) at room temperature. At the end of incubation, 
the wells were washed 3 times with wash buffer and, after have properly dried the plate, 
150 μl of TMB substrate were pipetted into each well at timed intervals. The plate was 
once again incubated on the shaker at room temperature for 10-15 min, or until 
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Calibrator A attains dark blue color. At this time, 50 μl of stopping solution were 
injected into each well at the same timed intervals registered while pipetting TMB. The 
plate was read on a micro well plate at 450 nm within 20 min after addition of the 
stopping solution.  
Cross-reactivity with other steroids is typically less than 1% and cross-reactivity with 
progesterone is 6% (IBL, Hamburg, Germany). The sensitivity of the assay was 0.05 ng/
ml."
6.7 Chemistry of PBR 127-DOTA conjugates!
tert-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (a)  
In a flask containing CH2Cl2 (8 mL), 2-(2-(2-aminoethoxy)ethoxy)ethanol (1 mM, MW 
149.19) was dissolved, and Boc anhydride (1 mM, MW 218.25) and DIPEA (1 mM, 
101.19, d 0.742 g/ml) were added. The reaction was stirred at room temperature over 
night. Once completed, the solution was evaporated, the residue solubilized with some 
demineralized water and extract with EtOAc (10 mL x 3). The organic layer was 
collected and dried under vacuum, to achieve the final product (92% yield) as a 
transparent gel.  
1H-NMR (CDCl3, 200 MHz) δ: 1.37 (s, 9H, OC(CH3)3), 3.22 (t, 2H, CH2NH), 3.46 (t, 
2H, CH2OH), 3.53-3.58 (m, 6H, CH2CH2O), 3.66 (t, 2H, OCH2CH2NH).!
2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 4-methylbenzenesulfonate (b)  
A solution of a (0.92 mM, MW 249.30) in CH2Cl2 (5 ml) dried on molecular sieves, 
under N2 atmosphere, was stirred at room temperature. TEA (1 mM, MW 101.19, d 
0.728 g/ml) was added to the solution and then tosyl chloride (0.92 mM, MW 190.65). 
The reaction was carried out overnight. When finished demineralized water (2 x 5 ml) 
was poured in the flask, to wash out the unreacted chloride. Then the bulk in the flask 
was solubilized with the smallest amount of CH2Cl2, transferred in a falcon and 
precipitated with cold Et2O (7 ml). After 30 min at -4 °C, the flacon was centrifuged 
(3,000 rpm, 4 min), and the supernatant was collected. After repeating this procedure for 
two times, the whole volume of Et2O was evaporated under vacuum, to achieve the final 
product, b, as a transparent gel (83% yield).  
1H-NMR (CDCl3, 200 MHz) δ: 1.37 (s, 9H, OC(CH3)3), 2.37 (CH3Ph), 3.22 (t, 2H, 
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CH2NH), 3.53-3.58 (m, 6H, CH2CH2O), 3.72 (t, 2H, CH2OS), 3.79 (t, 2H, 
OCH2CH2NH), 7.48 (d, 2H, Ph), 7.76 (d, 2H, Ph).!
t e r t - b u t y l ( 2 - ( 2 - ( 2 - ( 4 - ( 3 - ( 2 - ( d i e t h y l a m i n o ) - 2 - o x o e t h y l ) - 5 , 7 -
b i s ( t r i fl u o r o m e t h y l ) p y r a z o l o [ 1 , 5 - a ] p y r i m i d i n - 2 -
yl)phenoxy)ethoxy)ethoxy)ethyl)carbamate (c)  
To a solution of 7F (0.7 mM, MW 460.37) in DMF (2 mL), were added K2CO3 (1.4 
mM, MW 138.21) and b (0.76 mM, MW 403.49). The reaction was stirred at 85 °C (± 5 
°C) overnight. When finished, demineralized water (2 ml) was dropped into the flask 
and the solution extracted with EtOAc (3 x 2 mL). The organic layers were collected 
and dried over Na2SO4, then filtered and evaporated until complete exsiccation.  
The final product, c, was achieved as a yellow semi-solid bulk (68% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.17 (t, 3H, N(CH2CH3)), 1.34 (t, 3H, N(CH2CH3)), 
1.47 (s, 9H, OC(CH3)3), 3.35 (t, 2H, CH2NH), 3.49 (dt, 4H, CH2O), 3.57 (q, 2H, 
N(CH2CH3), 3.67 (q, 2H, N(CH2CH3)2), 3.85 (t, 2H, CH2OPh), 3.88 (s, 4H, CH2CH2O), 
4.05 (s, 2H, CH2C=O), 7.02 (d, 2H, Ph), 7.39 (s, 1H, CH), 7.87 (d, 2H, Ph)."
2 - ( 2 - ( 4 - ( 2 - ( 2 - ( 2 - a m i n o e t h o x y ) e t h o x y ) e t h o x y ) p h e n y l ) - 5 , 7 -
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide (d)  
Compound c (0.47 mM, MW 691.66) was dissolved in CH2Cl2 (5 ml) and 30% TFA 
(1.5 ml, MW 114.02, d 1.49 g/ml) was added. The solution was stirred at room 
temperature for 3 h. The reaction was then evaporated to dryness and the residue was 
solubilized once again with the same percentage of CH2Cl2 and TFA. After 2 more h, 
the volume was evaporated, and the residue partitioned between a saturated aqueous 
solution of K2CO3 (2 ml) and CH2Cl2 (2 ml); the organic phase was collected and 
evaporated to give the final product d (80% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.17 (t, 3H, N(CH2CH3)), 1.27 (t, 3H, N(CH2CH3)), 
3.35 (t, 2H, CH2NH), 3.46 (dt, 4H, CH2O), 3.59 (q, 2H, N(CH2CH3), 3.61 (q, 2H, 
N(CH2CH3)2), 3.69 (m, 4H;2H-N(CH2CH3); 2H-CH2OPh), 3.89 (s, 4H, CH2CH2O), 4.08 
(s, 2H, CH2C=O), 7.03 (d, 2H, Ph), 7.04 (s, 1H, CH), 7.81 (d, 2H, Ph)."
tri-tert-butyl 2,2’,2’’-(10-(2-((2-(2-(2-(4-(3-(2-(diethylamino)-2-oxoethyl)-5,7-
b i s ( t r i fl u o r o m e t h y l ) p y r a z o l o [ 1 , 5 - a ] p y r i m i d i n - 2 -
y l ) p h e n o x y ) e t h o x y ) e t h o x y ) e t h y l ) a m i n o ) - 2 - o x o e t h y l ) - 1 , 4 , 7 , 1 0 -
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tetraazacyclododecane-1,4,7-triyl)triacetate (e)  
DOTA (tBu)3 (0.4 mM, MW 572.73) was dissolved in DMF (4 ml), with HATU (0.4 
mM, MW 380.23) and NMM (0.04 ml, MW 101.15, d 0.92 g/ml). Then, compound d 
(0.38 mM, MW 591.55) was added and the solution was stirred at room temperature 
over night. When finished, demineralized water (2 ml) was poured into the flask, and the 
solution extract with CH2Cl2. The organic phase was collected, dried over Na2SO4, 
filtered and reduced in volume, and cold Et2O (7 ml) was added drop wise until the 
formation of a precipitate. After centrifugation (3,000 rpm, 4 min), the supernatant was 
evaporated to reach the final product e (72% yield).  
1H-NMR (CDCl3, 400 MHz) δ: 1.10 (t, 3H, N(CH2CH3)), 1.17 (t, 3H, N(CH2CH3)), 
1.44 (s, 27H, t(Bu)), 2.79 (s, 16H, CH2CH2 DOTA), 3.42-3.69 (m, 14H; 8H-CH2C=O 
DOTA; 4H-N(CH2CH3)2; 2H-CH2NH), 3.78 (t, 4H, CH2CH2O), 3.86 (s, 4H, 
CH2CH2O), 4.02 (s, 2H, CH2C=O), 4.18 (t, 2H, CH2OPh), 7.01 (d, 2H, Ph), 7.36 (s, 1H, 
CH), 7.80 (d, 2H, Ph)."
2 , 2 ’ , 2 ’’ - ( 1 0 - ( 2 - ( ( 2 - ( 2 - ( 2 - ( 4 - ( 3 - ( 2 - ( d i e t h y l a m i n o ) - 2 - o x o e t h y l ) - 5 , 7 -
b i s ( t r i fl u o r o m e t h y l ) p y r a z o l o [ 1 , 5 - a ] p y r i m i d i n - 2 -
y l ) p h e n o x y ) e t h o x y ) e t h o x y ) e t h y l ) a m i n o ) - 2 - o x o e t h y l ) - 1 , 4 , 7 , 1 0 -
tetraazacyclododecane-1,4,7-triyl)triacetic acid (f)  
To a solution of e (0.015 mM, MW 1,161.30) in CH2Cl2 (4 ml), TFA (0.17 ml, MW 
114.02, d 1.49 g/ml) was added slowly and the solution was stirred at room temperature 
for 1 h. After that, the CH2Cl2 was evaporated and fresh TFA was added in the flask, 
stirring overnight. The latter procedure was repeated twice. When completed, the 
volume of the solution was reduced and cold Et2O (7 ml) was added slowly, until the 
formation of a yellow precipitate. After centrifugation (3,000 rpm, 4 min) and removal 
of the supernatant, the final product f was achieved as deep yellow solid, after two 
washing with Et2O and exsiccation.  
1H-NMR (CD3)2CO, 400 MHz) δ: 1.10 (t, 6H, N(CH2CH3)2), 2.05 (s, 16H, CH2CH2 
DOTA), 3.41-3.81 (m, 22H; 8H-CH2C=O DOTA; 4H-N(CH2CH3)2; 4H-CH2CH2O; 2H-
CH2NH; 4-CH2CH2O), 4.15 (s, 2H, CH2C=O), 4.26 (t, 2H, CH2OPh), 7.14 (d, 2H, Ph), 
7.85 (s, 1H, CH), 7.92 (d, 2H, Ph).   
UPLC/ESI-MS: m/z 977 M+; 978 [M + 1], 489 [(M + 2H)/2]+. 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The crude was purified on 200 Å C18 reverse-phase column, gradient 407030 (see 
indication before)."
6.8 Membrane preparation and binding assay!
See directions above (par. 6.4)."
6.9 Labeling procedure of compound f (Department of Nuclear Medicine, Azienda 
Ospedaliera di Careggi, Florence).!
111In.  
A solution of f (2 mg/ml) in CH3CN/H2O (10:90, 50 μl CH3CN + 450 μl milli q water) 
was prepared, aliquoted and, a part from the fraction immediately used aliquoted and 
stored at -20 °C.  
HPLC-UV of the compounds was performed, to define the tR (11.35 min), both on an 
aliquot of the f solution maintained at +4 °C for 24, on an aliquot defrosted after 24 h at 
-20 °C and on an aliquot defrosted after 24 h at -20 °C and subsequently incubated at 90 
°C for 20 min, to validate the temperature-related stability.  
A TLC on 111InCl was performed too, to determine its tR (~ 0.9 min).  
  
During the first labeling trial, the solution 2 mg/ml of compound f was diluted to a 
solution of 1 mg/ml, with ammonium acetate buffer 0.2 M, pH 4-5. 10 μl of this 
solution (1.02 mM) were collected with 100 μl of ammonium acetate buffer 0.2 M, 
gentisic acid (10 μg/900 μl) 90 μl and 111In chloride, and the mixture (final volume of 
200 μl) was incubated for 20’ at 90°C.  
When completed, quality control was performed to asses the radiochemical purity, by 
means of TLC and HPLC (analytic specs above). Measurement of the pH gave back a 
value of 5.  
The TLC radiochemical purity shown 3 peaks: tR ~ 0, ascribable to 111In labeled 
compound f (32.7%); tR ~ 0.4, unidentified (21.0%); tR ~ 0.9, ascribable to unlabeled 
111In (46.2%).  
The HPLC radiochemical purity highlighted the presence of several peaks, the main of 
which attributable to unlabeled 111In (36.92%, tR 3.19 min) and to 111In labeled 
compound f (18.68%, tR 11.31 min). Five more peaks were displayed, with tR between 
4.24 and 10.2 min, accounting for the 44.39% of the total residual activity.  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After the quality control tests, the mixture was purified on Sep Pak light C18 column 
(previously conditioned with EtOH 5 ml and milli q water 15 ml). Once charged the 
sample, the C18 was dried with pressurized air; after that, the C18 was washed twice 
with milli q water and dried with pressurized air; finally, 0.5 ml EtOH was flowed 
through before the last drying with pressurized air.  
On the elute phase, with a measured activity of 150 μCi (labeling yield of 21%), new 
quality control tests were done. The TLC analysis shown the lack of unlabeled 111In 
peak (tR ~ 0.9) and the presence of the peak with of the 111In labeled compound f 
(72.1%, tR ~ 0) and of a wide band at  tR ~ 0.2 (27.8%). The HPLC results confirmed the 
absence of unlabeled 111In and the presence of a remarkable peak (tR 11.34 min) due to 
the 111In labeled compound f, together with the presence of three more peaks (tR 4.19, 
8.33 and 10.07 min, with percentage value, respectively, of 8.87, 21.62, 10.92).  
At the end of this procedure, the resulting purified solution was dried for 5 min at 90 °C 
under a flow of helium, then resuspended in 200 μl of saline solution (NaCl 0.9%) and 
analyzed one more time for the radiochemical purity, with a final value of about 73.8% 
of the whole residual activity ascribable to 111In labeled compound f deriving from TLC 
and of 51.56% from HPLC.   
The same procedure already described was use for six more labeling trial, varying the 
temperature and duration of reaction, in one case exchanging the ammonium acetate 
with a Hepes buffer and, in four cases, not adding gentisic acid to the mixture. Best 
results were achieved at 60 °C for 30 min, in ammonium acetate buffer and with no 
gentisic acid added: in this case, the TLC radiochemical purity had a value of about 
77.3% and the HPLC radiochemical purity a value of 75.9%.  
 
Reaction mixture labeling trial 1:  
- ammonium acetate buffer 0.2 M (100 μl);  
- compound f 1 mg/ml (10 μl); 
- gentisic acid 10 mg/900 μl (90 μl);  
- 111In chloride (100 μl).  
Stirred at 90 °C for 20 min. Labeling yield: 21%; radiochemical purity by HPLC: 
57.7%;  radiochemical purity by TLC 72.1%."
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Reaction mixture labeling trial 2:  
- ammonium acetate buffer 0.2 M (200 μl);  
- compound f 1 mg/ml (20 μl); 
- gentisic acid 10 mg/900 μl (180 μl);  
- 111In chloride (200 μl).  
Stirred at 90 °C for 20 min. Labeling yield: 19%; radiochemical purity by HPLC: 
31.4%;  radiochemical purity by TLC 67.3%."
Reaction mixture labeling trial 3:  
- ammonium acetate buffer 0.2 M (100 μl);  
- compound f 1 mg/ml (10 μl); 
- gentisic acid 10 mg/900 μl (90 μl);  
- 111In chloride (50 μl).  
Stirred at 45 °C for 40 min. Labeling yield: 12%; radiochemical purity by HPLC: 
27.7%;  radiochemical purity by TLC 54.4%."
Reaction mixture labeling trial 4:  
- ammonium acetate buffer 0.2 M (200 μl);  
- compound f 0.1 mg/ml (10 μl); 
- 111In chloride (50 μl).  
Stirred at 60 °C for 30 min. Labeling yield: 22%; radiochemical purity by HPLC: 
75.9%;  radiochemical purity by TLC 77.3%."
Reaction mixture labeling trial 5:  
- Hepes buffer 0.1 M (250 μl); 
- compound f 0.1 mg/ml (10 μl); 
- 111In chloride (50 μl).  
Stirred at 60 °C for 30 min. Labeling yield: 13%; radiochemical purity by HPLC: 
51.9%;  radiochemical purity by TLC 70.8%."
Reaction mixture labeling trial 6:  
- ammonium acetate buffer 0.2 M (250 μl);  
- compound f 0.1 mg/ml (10 μl); 
- 111In chloride (50 μl).  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Stirred at 65 °C for 60 min. Labeling yield: 1.75%; radiochemical purity by HPLC: 
27.0%;  radiochemical purity by TLC 52.7%."
Reaction mixture labeling trial 7:  
- ammonium acetate buffer 0.2 M (250 μl);  
- compound f 0.1 mg/ml (10 μl); 
- 111In chloride (100 μl).  
Stirred at 70 °C for 30 min. Labeling yield: 16%; radiochemical purity by HPLC: 
54.7%;  radiochemical purity by TLC 78.2%."
6.10 General procedure for the labeling of compound f with 68Ga (IEO, European 
Institute of Oncology, Milan)"
A solution of f (2 mg/ml) in CH3CN/H2O (10:90, 50 μl CH3CN + 450 μl milli q water) 
was aliquoted.  
HPLC-UV (220 nm and 280 nm) of the compounds was performed, to define the tR 
(12.67 min).  
10 μl of the solution were diluted with 30 μl of H2O, and then 40 μl of this second 
solution were collected in the reaction vessel of the synthesis module, together with 200 
μl of sodium acetate buffer 1 M and 1 ml of physiological saline. The vessel was 
preheated at 95 °C. When the activity measured in the generator was enough (near 
35/37 mCi, that is about 12 pM of 68Ga), the 68Ga was eluted with diluted HCl, and the 
flow was poured into the vessel (final volume of about 4 ml). Then, the temperature was 
increased to 100 °C and the solution was left to react for 8 min. After that, the solution 
was pumped out of the vessel through a C18 Sep-Pak Cartridge, and washed once with 
physiological saline, to remove the free 68Ga, and then with 1 ml of EtOH 50%, to elute 
the labeled compound together with the other products originated during the reaction.  
The EtOH eluted phase was diluted with 1 ml of physiological saline, for a final volume 
of 2 ml. The activity measured in 1.5 ml of this solution was 4.3 mCi.  
Labeling yield: 30%; radiochemical purity by HPLC: 56%.
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